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Parkinson's disease (PD) is a common neurological disorder that causes problems in motor 
control as well as non-motor symptoms, such as dementia. Although the majority of PD 
cases are sporadic, at least 10% of cases are caused by a genetic defect and therefore 
inherited. The first mutation identified to cause PD was in a gene named SNCA, which 
makes a protein called α-synuclein (αSyn). This protein is also implicated in dementia with 
Lewy bodies and multiple system atrophy. Although the first mutation identified in αSyn 
caused a change of one amino acid, subsequent familial mutations were characterised to be a 
duplication or triplication of the SNCA gene. Patients with SNCA triplication mutations were 
always more severity affected by PD than patients with SNCA duplication mutations, such as 
an earlier age of onset and more rapid progression of disease.  This clinical information 
demonstrated that disease severity is positively correlated with SNCA gene copy number. 
In an attempt to model this αSyn dose-dependent affect on PD severity with human neurons, 
I have established a collection of genetically-engineered (transgenic) human embryonic stem 
cell (hESC) lines that over-express different levels of αSyn. I first showed that elevated αSyn 
expression does not affect the ability of hESCs to grow in a culture dish, and it does not 
affect their ability to make neurons when instructed to do so. I identified two transgenic 
hESC lines with different levels of αSyn expression – one line had high αSyn expression and 
the second line had normal αSyn expression. I first transformed both lines into forebrain 
(cortical) neurons using an established method, and then compared the rate of reactive 
oxygen species (ROS) production in high versus normal αSyn expressing nerve cells. High 
levels of ROS production indicate unhealthy nerve cells. I observed a significantly elevated 
level of ROS production in αSyn over-expressing neurons in less mature neurons suggesting 
they are in an unhealthy state. However, when I examined more mature neurons I did not 
observe a difference in ROS production between the high and normal αSyn expressing nerve 
cells. This suggests that either the immature nerve cells had died and were no longer present 
in later cultures, or they had recovered from the high levels of ROS production and were 








α-Synuclein (αSyn) is a small intrinsically disordered protein that drives the progression of a 
group of neurological disorders known of synucleinopathies, including Parkinson's disease, 
dementia with Lewy bodies and multiple system atrophy. Increased expression of αSyn due 
to gene duplication or triplication causes familial forms of these diseases, of which the 
severity is positively correlated with the gene copy number. Despite extensive efforts using 
various models, the precise mechanisms of αSyn toxicity in neurons have not been 
elucidated.  This could be partly due to biological differences between the models and 
authentic human neurons.  
In an attempt to model synucleinopathies with human neurons, I have established a 
collection of transgenic human embryonic stem cell (hESC) lines over-expressing αSyn. I 
first showed that elevated αSyn expression does not affect hESC proliferation and their 
differentiation potential towards neurons. Then I identified transgenic hESC lines that 
maintained high αSyn expression in differentiated neurons and compared the rate of reactive 
oxygen species (ROS) production in high versus normal αSyn expressing cortical neuronal 
cultures. I observed a significantly elevated level of ROS production in αSyn over-
expressing neurons in less mature neurons; however, there was no difference observed in 
more mature neurons. The possible reasons that lead to this difference are discussed.  
This is the first report of stable αSyn overexpressing hESC lines, which can provide an 
unlimited source of human neurons for studying the mechanism underlying neuronal cell 










αSyn  α-synuclein, alpha-synuclein 
AD  Alzheimer’s disease 
AST  Alpha-synuclein triplication (iPS cell line) 
ATP  Adenosine triphosphate 
βSyn  β-synuclein, beta-synuclein 
γSyn  γ-synuclein, gamma-synuclein 
BDNF  Brain-derived neurotrophic factor 
BMP  Bone morphogenetic protein 
cDNA  Complementary DNA 
CNS   Central nervous system 
DLB  Dementia with Lewy bodies 
DMEM  Dulbecco’s modified eagle’s medium 
DNA  Deoxyribose nucleic acid 
DTT  Dithiothreitol 
EDTA  Ethylenediaminetetraacetic acid 
FACS  Fluorescence-activated cell sorting 
FCS   Foetal calf serum 
FGF2  Fibroblast growth factor 2 
GDNF  Glial-derived neurotrophic factor 
GFAP  Glial fibrillary associated protein 
GFP  Green fluorescent protein 
HBSS Hank’s buffered saline solution 
hES Human embryonic stem (cell) 
hESC  Human embryonic stem cell 
HRP  Horseradish peroxidase 
ICM  Inner cell mass 
iPS  Induced pluripotent stem (cell) 
IRES  Internal ribosome entry site 
KSR  Knockout serum replacement media 
LBs   Lewy bodies 
mES  Mouse embryonic stem (cell) 
MPTP   1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine 
vi 
  
MSA   Multiple system atrophy 
MTS assay   CellTiter 96® AQueous One Solution Reagent assay 
NAC  Non-amyloid component 
NAS  Normal Alpha-Synuclein (iPS cell line) 
OCT4  Octamer-binding transcription factor 4, POU class 5 homeobox 1 
OTX2  Orthodenticle homologue 2 
PAX6  Paired box gene 6  
PBS  Phosphate buffered saline 
PD  Parkinson’s disease 
ROS   Reactive oxygen species 
RNA  Ribose nucleic acid 
RPM  Revolutions per minute 
ROCK  Rho-associated protein kinase 
RT-qPCR  Reverse transcriptase quantitative polymerase chain reaction 
SDS  Sodium dodecyl sulphate 
SNARE  Soluble N-ethylmaleimide–sensitive factor attachment protein receptor 
SNCA Synuclein, alpha (non A4 component of amyloid precursor) 
SOX7  SRY (sex determining region Y)-box 7 
SOX17  SRY-box 17 
TGFβ  Transforming growth factor beta 
TuJ1  β-III-tubulin antigen  
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1.1 Thesis introduction 
The protein α-synuclein (αSyn) has gained considerable research interest in recent years due 
to its strong association with a group of incurable, progressive neurodegenerative diseases 
collectively known as synucleinopathies. The protein is a major component of LBs 
(Spillantini et al., 1997), a pathological hallmark of Parkinson’s disease (PD) and dementia 
with Lewy bodies (DLB), and its mutant forms can cause familial PD (Kruger et al., 1998; 
Polymeropoulos et al., 1997; Singleton et al., 2003; Zarranz et al., 2004). These findings 
suggest that αSyn may have a key role in governing the mechanism underlying the aetiology 
and progression of neurodegeneration in these conditions.  However, the pathogenic 
mechanism caused by αSyn has not been fully understood, hindering the development of 
therapeutic approaches.  
Lack of an experimental model that fully recapitulates key features of the diseases is a 
central problem in this research area. As access to patient tissue is limited, most in vitro 
studies rely on animal tissue, human cancer cell lines or primary cell lines, such as 
fibroblasts. These models lack either neuronal aspects or human genetic background, which 
may contribute to failure in manifestation of the disease phenotypes. To sum up, since 
current available models have not provided a clear understanding of the disease mechanism, 
the development of new models is needed. 
Human embryonic stem (hES) cells are pluripotent cell lines isolated from the inner cell 
mass (ICM) of blastocysts (Thomson et al., 1998). Their capacity to differentiate into 
neurons and self-renew in vitro presents an unlimited experimental resource to study 
neurodegenerative conditions at the cellular level. The advantage of hES cells is that they are 
amendable to genetic modification, providing an opportunity to model genetic forms of 
synucleinopathies.  
This thesis presents transgenic human embryonic stem cell (hESC) lines as a tool for 
modelling synucleinopathies. Specifically, the focus is on increased WT-SNCA expression, 
which represents one form of genetic PD. In human, SNCA triplication or duplication causes 
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PD inherited in autosomal dominant manner (Ibanez et al., 2004; Singleton et al., 2003). 
Clinically, the severity of disease is positively correlated with the SNCA gene dosage (Fuchs 
et al., 2007); however, this correlation has not been proven in vitro. Induced pluripotent cell 
(iPS) cells derived from patients with SNCA triplication recently have been established 
(Devine et al., 2011). However, whether the models exhibit disease phenotypes remains to 
be elucidated.  Also, like other forms of PD, the pathogenesis caused by increased WT-
SNCA is poorly understood.  
Employing random insertional transgenesis using plasmid DNA, a set of clonal transgenic 
Shef4 hESC lines constitutively expressing different levels of αSyn were established. The 
models were evaluated for differentiation potential toward cortical neurons and phenotypes 
were investigated by determining levels of reactive oxygen species (ROS) production and 
cell death. The analyses revealed promising results supporting the potential of the models to 
be very useful in PD research in the future. To my knowledge, this is the first demonstration 
of the use of transgenic SNCA-hESC lines as a tool for modelling synucleinopathies in vitro. 
However, as some limitations were encountered, the thesis suggests future experiments to be 
undertaken to get more out of the models and ways to overcome these limitations. 
The thesis begins with a chapter of literature review of the protein αSyn and its association 
with synucleinophaties. The later part of the chapter reviews the technology of random 
insertional transgenesis of hES cells using plasmid DNA, and a brief summary of currently 
used protocols for in vitro neural differentiation of hES cells. Chapter 2 describes materials 
and methods used in the research. Chapter 3 presents data on the generation of transgenic 
Shef4 hESC lines, which begins with construction of the expression plasmids. When the 
transgenic Shef4 hES cell lines were obtained, they were characterised for SNCA expression, 
gene silencing during hESC propagation, and rate of cell proliferation. Chapter 4 presents 
further characterisation of the transgenic lines and phenotypic analysis of neurons derived 
from selected transgenic hES cell lines. The characterisation includes neural differentiation 
potential and transgene expression during neural differentiation. The later part of this chapter 
presents ROS production and cell death analysis of neurons derived from selected transgenic 
hESC lines. The final chapter discusses limitations of the work and future experiments to 
further evaluate the models. It also suggests how to get the most out of the current models 
and ways to construct improved versions to overcome some of the limitations presented.  
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1.2. Thesis hypothesis and aims 
I aim to answer the question of whether transgenic hESC lines stably over-expressing αSyn 
can be used to generate neurons for modelling synucleinopathies.  
My hypothesis is that αSyn over-expressing hES cells can efficiently differentiate into 
neurons and will exhibit elevated ROS production and cell death, which is part of the 
pathogenic phenotype of synucleinopathies. 
Aims: 
1. To establish a collection of transgenic hESC lines with different levels of SNCA 
expression. 
2. To characterise the transgenic hESC lines by means of  
a. The stability of transgene expression during hESC propagation and during 
neural differentiation. 
b. The impact of increased SNCA expression on differentiation potential 
towards the neural lineage.  
3. To produce cortical neurons from the transgenic hESC lines. 
4. To investigate ROS production and cell death in the neurons derived from the 






1.3 αSyn gene and protein 
1.3.1 Discovery  
In 1980, antiserum against highly purified cholinergic vesicles extracted from electric rays 
was generated and shown to bind synaptic vesicles (Carlson and Kelly, 1980). In an attempt 
to identify the gene encoding the synaptic-specific protein, the serum was used to screen a 
cDNA expression library generated from electromotor nuclei of Torpedo californica 
(Maroteaux et al., 1988). Using this approach, a neuron-specific gene was identified, and 
further immunostaining showed its protein product to be localized on the nuclear envelope 
and presynaptic nerve terminal. This unique expression pattern led the authors to name it 
synuclein.   
In 1993, a protein precursor of Non-Aβ-Amyloid Component (NAC), a component of 
amyloid plaques of Alzheimer’s disease (AD) was identified, and named NACP (Ueda et al., 
1993). NACP and αSyn were known to be the same protein when synucleins were identified 
in human. Human α- and β-synuclein (βSyn) were first isolated from human brain samples 
with sizes of 134 and 140 amino acids, respectively (Jakes et al., 1994) whereas γ-synuclein 
(γSyn) was identified later with size of 127 amino acids (Ji et al., 1997).  
1.3.2 Protein structures and domains  
The synuclein family is currently classified into 3 groups; α-, β-, and γSyn. The proteins are 
characterised by imperfect repeats, which have a core consensus of KTKEGV present 
mainly in a highly conserved N-terminus. The acidic C-terminal domain is divergent, and 
this distinguishes each synuclein member (Figure 1.1A). Human αSyn is more closely 
related to βSyn than to γSyn (Figure 1.1B and Figure 1.1C). 
αSyn can be divided into 3 major domains; amphipathic domain, NAC region (residues 61-
95) and acidic tail. Only the first two domains participate in formation of α-helical structures 
when interacting with lipids whereas the acidic part stabilizes the binding. NAC domain, 
known as a component of amyloid plaques, has an essential role in vitro fibrillization of 
αSyn (Giasson et al., 2001). The domain contains a hydrophobic stretch of 12 amino acids 




Figure 1.1 Amino acid sequence alignments of human synucleins.  
A) α-, β- and γ-synucleins 
B) α- and β-synucleins  
C) α- and γ-synucleins  
Box shaded as black and grey indicate consensus sequences in all three and that in two classes of synucleins, respectively. Note that the N-terminus is 
conserved among the synucleins, and that αSyn is more related to βSyn than to γSyn.
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Due to its association with synaptic vesicles, αSyn was believed to bind to vesicle 
membranes as part of its normal function. Upon binding to lipid, αSyn acquires α-helical 
structure from residues 9-89, which includes the 7 imperfect repeats of 11 amino acids 
(Figure 1.2A) (Alderson and Markley, 2013). The amino acids in this region form an 
amphipathic α-helix with polar and charged amino acids on one face of the helix and apolar 
amino acids on the opposite face (Figure 1.2B). The polar face is exposed to the aqueous 
environment of the cytosol while the apolar face interacts with hydrophobic lipid tails of the 
phospholipid bilayer. The lysine residues in the repeat domains reside at the polar-apolar 
interface, interacting with lipid head groups of the phospholipid bilayer.   
Based on studies using membrane mimics, two helical conformations of αSyn have been 
proposed; the two broken helices and a single extended helix. The conformations of αSyn are 
affected by the size and content of membrane, and solution condition. It is likely that 
membrane size affects αSyn conformation as it determines the curvature of membrane 
surface. When binds to membrane with more curvature, such as a micelle, αSyn exists as a 
broken-helix (Figure 1.2C).  However, with larger and less curvature membrane, such as 
vesicle, αSyn adopts a single extended helix (Alderson and Markley, 2013). Similar to 
membrane size that influence αSyn conformation via determining the curvature of 
membrane, lipid content and SDS concentration determines the shapes of micellar SDS to be 
either high-curvature spherical or low-curvature cylindrical micelles (Ferreon et al., 2009; 
Georgieva et al., 2010). Moreover, with a certain range of ratio of lipid- or SDS-to-protein 
(αSyn), αSyn can interconverts between the two conformations, which results in coexisting 
of broken-helix and extended helix conformations (Ferreon et al., 2009; Georgieva et al., 
2010). This conformational conversion of αSyn may mediate its function on vesicle fusion 
(Georgieva et al., 2010).  
Apart from lipid-bound, free αSyn has been studied extensively (Alderson and Markley, 
2013). Initial studies agreed that αSyn was intrinsically disordered existing mostly as random 
coils and lack of secondary structure in solution.  However, later studies demonstrated that 
free αSyn can partially fold, having internal interaction between residues in the N- and C- 
termini. A recent controversial proposal is that αSyn exists natively as tetramer 






Figure 1.2 Amino acid sequences, domains and a proposed structure of human αSyn. 
A) Amino acid sequences and domains. The 7 imperfect repeats of 11-amino acids 
are highlighted in orange and grenn. Each repeat is given a Roman numeral. The 
shaded boxes under the sequences indicate 3 domains of the protein; the 
amphipathic domain (grey), NAC (light blue), and the acidic domain (red). 
(Adapted from Anderson and Markley, 2013).   
B) The α-helical wheel of the 7 imperfect repeats. The wheel is separated radially 
into a polar domain and a hydrophobic domain by lysine residues. The polar 
domain is proposed to face the cytosol whereas the other is buried in the 
hydrophobic environment of the phospholipid bilayer. The positively charged 
residue, lysine, is believed to bind to the negatively charged head groups of the 
bilayer. Numbers indicate positions within the repeats. Colours indicate properties 
of the amino acid side chains; blue: basic, red: acidic, purple: polar uncharged, 
black: nonpolar. (Adapted from Bendor et al., 2013).   
C) Two broken-helical structure of αSyn. While binding to micelles, αSyn adopts 
two anti-parallel helices, which are formed by the amphipathic domain and NAC. 
The colours correspond to protein domains shown in A). (Adapted from Pfefferkorn 
et al., 2012 ).  
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1.3.3 Expression of αSyn 
αSyn is encoded by the gene SNCA located on chromosomes 4q22.1 (Chen et al., 1995). It is 
well documented that αSyn is enriched in the brain. Purified human αSyn is present in the 
cytosolic fraction of the brain homogenate with apparent molecular mass of approximately 
19 kDa (Jakes et al., 1994; Ueda et al., 1993), which is higher than a calculated molecular 
mass, 14.7 kDa (Jakes et al., 1994). The higher apparent molecular mass is believed to be 
caused by the negatively charged carboxyterminal of the protein (Jakes et al., 1994).  
Beside intense expression in the brain, αSyn is also distributed in other tissues. SNCA 
mRNA is detected in a significant level in placenta, low level in kidney, heart, lung, red 
blood cells and skeleton muscle and no detectable in liver (Scherzer et al., 2008; Ueda et al., 
1993). The protein is also observed in sensory system during early mouse embryonic 
development (Zhong et al., 2010). 
In human, αSyn is detected as early as 11-week gestation in cortical plate whereas in mouse, 
the protein is found at E9.5 in the midbrain/hindbrain junction (Raghavan et al., 2004; Zhong 
et al., 2010). Zhong and colleagues show that in various regions of the embryonic mouse 
brain, αSyn expression follows a spatio-temporal pattern that matched the neuronal 
migratory pathway and the formation of synaptic connections (Zhong et al., 2010). For 
example, in cerebral cortex, where neuron migration happens during preplate division into 
two discrete layers; marginal zone (MZ) and subplate (SP), αSyn, which is initially detected 
at E12.5 in preplate, is sequentially expressed strongly in MZ and SP, where synapses are 
formed (Zhong et al., 2010).  The results are consistent with a steep increase of αSyn when 
synaptophysin is increasing. This interval coincides with redistribution of the protein from 
neuronal cell body to the nerve terminal (Hsu et al., 1998).  
During early brain development, αSyn exhibits dynamic subcellular localisation (Zhong et 
al., 2010). In early embryonic stages of mouse, the protein is found in the nuclei as well as in 
the cytoplasm and the processes of neurons. Then, in later stages, most of the αSyn is 
localized in the non-nuclear compartments (Raghavan et al., 2004; Zhong et al., 2010). 
Consistent with this, developing human brain also exhibited changes of αSyn subcellular 
localisation (Raghavan et al., 2004).  
Nuclear localisation of the αSyn suggested that it might have a transcriptional regulatory role 
in neuronal nuclei. It is worth nothing that nuclear and cytoplasmic αSyn seems to have 
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different molecular structures (Yu et al., 2007; Zhong et al., 2010). Yu and colleagues have 
generated two antibodies that recognised different epitopes of αSyn (Yu et al., 2007).  Both 
antibodies can detect nuclear and cytoplasmic αSyn by western blotting. However, only one 
of them can detect nuclear αSyn by immunofluorescence. The results implied that nuclear 
αSyn may have a structure that limits access of the antibody to the epitopes, which were 
revealed by denaturing in western blotting (Yu et al., 2007).  
1.3.4 Physiological function of αSyn 
Neurotransmission and synaptic plasticity 
While presynaptic localization of αSyn is well documented, its function on this site is not as 
dramatic as expected. Mice lacking αSyn exhibited normal basic synaptic function with 
minor neurological deficits (Abeliovich et al., 2000; Cabin et al., 2002; Chandra et al., 
2004). αSyn is only required for some synaptic activities in particular circumstances, for 
example, in response to extensive stimulations or during aging (Burre et al., 2010; Cabin et 
al., 2002), and may work redundantly with the two other synucleins (Chandra et al., 2004; 
Vargas et al., 2014). 
αSyn appears to be implicated in modulating the nigrostriatal dopamine system. αSyn alone 
or together with βSyn was demonstrated to be required for maintaining normal DA levels in 
the striatum. In one study, αSyn null mice displayed a reduction in nigrostriatal DA 
(Abeliovich et al., 2000) whereas similar result  was observed only in double αSyn/ βSyn 
knockout mice, but not in individual αSyn or βSyn knockout mice (Chandra et al., 2004); 
thus, suggesting functional redundancy of these two synucleins. As there was no change in 
the degradation rate of DA, it was likely that a reduction of DA level was a result of 
decreased synthesis or storage (Abeliovich et al., 2000; Chandra et al., 2004). Moreover, 
neurons lacking αSyn exhibited increased DA release in response to paired stimuli; thus, 
suggesting an inhibitory role of αSyn in DA release under this condition (Abeliovich et al., 
2000). 
Several mechanisms have been proposed to explain how αSyn may modulate the DA system. 
αSyn has been implicated in regulating synaptic vesicle biology, including vesicle 
endocytosis, exocytosis, and trafficking. During vesicle exocytosis to release 
neurotransmitter, αSyn promotes SNARE complex assembly. Deletion of CSPα resulted in 
inhibition of SNARE complex assembly, which could be rescued by transgenic expression of 
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αSyn (Chandra et al., 2005). A recent study further demonstrated that αSyn promotes 
SNARE complex assembly by direct binding to a SNARE-protein synaptobrevin2/ vesicle-
associated membrane protein2 (VAMP2) (Burre et al., 2010). Sustaining SNARE complex 
assembly by αSyn appeared important for neurological function during aging, but not in 
early development. Triple-knockout of all synucleins caused severe neurodegeneration in 
aging mice, which subsequently died prematurely. These animals did not have an obvious 
phenotype when they were young, despite a significant reduction in SNARE complex 
assembly (Burre et al., 2010).  
αSyn may regulate neurotransmission by modulating synaptic vesicle endocytosis, which is a 
process for vesicle recycling at presynaptic nerve terminals. Recent studies demonstrated 
that αSyn enhanced synaptic vesicle endocytosis. (Ben Gedalya et al., 2009; Vargas et al., 
2014). In this process, synucleins work redundantly, by which individual expression of each 
synuclein member could rescue defective endocytosis in triple synuclein-null neurons 
(Vargas et al., 2014) .  
αSyn may modulate neurotransmission by altering release probability of neurotransmitters. 
More specifically, αSyn may regulate the number of vesicles available for neurotransmitter 
release by governing the mobilization of synaptic vesicles from reserve pool to readily 
releasable pool, for example, by controlling the size of reserve pool and/or resting pool 
(Cheng et al., 2011). Suppression of αSyn using antisense oligonucleotides in rat 
hippocampal neurons resulted in significant reduction in distal synaptic vesicle pool without 
affecting docked vesicles (Murphy et al., 2000). Similar results were observed in the 
hippocampal neurons of αSyn-deficient mice (Cabin et al., 2002). 
Brain lipid metabolism and mitochondrial functions 
αSyn may modulate turnover and incorporation of fatty acid in brain phospholipids 
(Golovko et al., 2007). In mice lacking αSyn, incorporation rates of two major 
Polyunsaturated Fatty Acids (PUFA) in the brain is altered (Golovko et al., 2005; Golovko et 
al., 2007). Consistent with this, another study showed that loss of αSyn leads to alterations in 
fatty acid content and  metabolism of brain phospholipids, and in biophysical properties of 




Interestingly, lack of αSyn also resulted in decreased cardiolipin, a mitochondrial membrane 
associated phospholipid, while other major phospholipids were unchanged (Ellis et al., 
2005). Moreover, the mice exhibited impaired complex I/III function. Taken together with 
the fact that cardiolipin is enriched in the mitochondrial inner membrane, where electron 
transport takes place, the results suggest that αSyn may affect the function of the electron 
transport chain. Indeed, it has been demonstrated that αSyn is associated with mitochondrial 
membrane in basal conditions (Devi et al., 2008a; Li et al., 2007) . Its interaction with 
mitochondria is believed to occur via a direct binding to cardiolipin (Nakamura, 2013). 
However, the detailed function of αSyn in mitochondria is still mostly unknown. 
1.3.5 Link to disease 
In 1993 Ueda et al. identified a component of Alzheimer’s amyloid plaques to be αSyn, 
known as NAC precursor (NACP) at the time (Ueda et al., 1993). It raised the question of 
whether αSyn was involved in other neurodegenerative diseases. In 1997 Polymeropouros 
and colleagues demonstrated for the first time that a point mutation in the SNCA gene is 
linked to a familial form of Parkinson’s disease (PD) (Polymeropoulos et al., 1997). This 
work suggested αSyn could initiate or potentiate the pathogenesis of PD. This hypothesis is 
supported by the finding that αSyn is a major component of Lewy bodies (LBs), a 
pathological hallmark of PD. Spillantini and colleagues showed that LBs from PD and DLB 
could be identified using antibodies raised specifically against αSyn (Spillantini et al., 1997), 
which later replaced the conventional methods relying on staining for ubiquitin and 
neurofilament. After that, detailed descriptions of αSyn aggregates in LBs (Baba et al., 1998; 
Spillantini et al., 1998), and more mutations in SNCA have been reported (Fujioka et al., 
2014). Currently, it is known that aggregated αSyn is also a component of multiple 
pathological structures in several neurological conditions.  
1.4 Synucleinopathies 
1.4.1 Description and common pathologies 
Synucleinopathies is a group of progressive neurodegenerative disorders, which share 
common pathological lesions characterized by αSyn aggregates in neurons and glia. 
Parkinson’s disease (PD), DLB and multiple systems atrophy (MSA) are common 
synucleinopathies, which mainly affect the aging population. Despite common αSyn 
pathology, they differ in the affected brain regions and neural cell types, which results in 
different clinical symptoms.  
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αSyn pathology is present in various forms in different locations within the cell or even 
extracellular locations. LBs, the histological hallmark of PD and DLB, are in the cytoplasm 
of neurons, but can be extracellular, whereas glial cytoplasmic inclusions (GCIs) are found 
primarily in oligodendrocytes of MSA.  LBs can be classified into 2 types; classical 
brainstem LBs, which have dense core and halo, and less-defined structure cortical LBs. 
These αSyn deposits are present in variable density with different distribution patterns in the 
brain.  
Parkinson’s disease (PD)  
PD is the most common neurodegenerative movement disorder clinically characterized by a 
failure in movement control including resting tremor, bradykinesia, rigidity and postural 
instability. In addition to motor symptoms, PD patients also manifest non-motor symptoms, 
such as cognitive dysfunction and sleep disturbance (Jankovic, 2008).  Dementia is common 
in severe cases, which could lead to misdiagnosis of DLB. To distinguish PD with dementia 
(PDD) from DLB, a diagnosis of PDD is only given to PD patients whose dementia develops 
at least one year after parkinsonism motor symptoms begin. However, recent consensus 
criteria suggest using the collective term Lewy body disease to describe PDD, and DLB, 
since they are on the same spectrum of disease (McKeith et al., 2005).  
Pathologically, PD is characterized by the loss of dopaminergic neurons in the nigrostriatal 
pathway, which is important for motor function, and the presence of brainstem LBs. 
However, as the disease progresses, LBs are also present in the cerebral cortex (Braak and 
Del Tredici, 2009) (Figure 1.3C-D).  
Dementia with Lewy bodies (DLB)  
DLB is the second most common neurodegenerative dementia after AD. It is clinically 
characterized by progressive dementia with three core features including fluctuating 
cognition, recurrent visual hallucination and spontaneous parkinsonism.  
The pathological hallmark of DLB is LBs (Figure 1.3E-G), which spread in variable regional 
patterns and can be pathologically classified into brainstem predominant, limbic or 
transitional, and diffuse neocortical type pathology (McKeith et al., 2005). The incidence of 
limbic and diffuse neocortical type pathology is much higher than the brainstem predominant 
type (Fujishiro et al., 2008; Weisman et al., 2007). AD lesions in the form of senile plaques 
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and neurofibrillary tangles are frequently present in the cortical region, limbic area, and 
amygdala. However, the topographic stages of the lesions do not fit with DLB clinical 
symptoms. Studies showed that clinical features of DLB are positively correlated with 
Lewy-related pathology, and inversely related with the severity of AD pathology (Fujishiro 
et al., 2008; Merdes et al., 2003). 
Multiple system atrophy (MSA)  
MSA is a progressive neurodegenerative disease with oligodendroglial degeneration. The 
clinical manifestations include cerebellar and paramidal dysfunction (ataxia), parkinsonism 
and autonomic dysfunction.   
Accompanied with neurodegeneration in brainstem, olivopontocerebellar, striatonigral, and 
autonomic systems, pathological characteristic of MSA is αSyn -immunoreactive GCIs in 
oligodendroglia (Papp et al., 1989; Papp and Lantos, 1994). Not uncommon, abnormal αSyn 
aggregates are also present in the nuclei of glia, cytoplasm (NCIs) and nuclei (NNIs) of 
neurons, and dystrophic neurites (Figure 1.3A-B) (Papp and Lantos, 1994; Yoshida, 2007). 
GCIs are widely distributed throughout the central nervous system, especially in the white 
matter, where most affected areas include paramidal, extraparamidal, limbic and 





Figure 1.3 Pathological αSyn aggregates in MSA, PD and DLB. 
A) - B) Brain tissues from patients with MSA immunostained for αSyn. αSyn-
immunoreactive GCIs (arrowheads) and neuronal intracytoplasmic inclusions 
(arrows) in substantia nigra (A) and pontine nucleus (B). (Adapted from 
Wakabayashi et al.,1998). 
C) - D) Substantial nigra from patients with PD immunostained for αSyn. Lewy 
neurites and a nerve cell with four cytoplasmic LBs. Scale bars are equivalent to 30 
µm in C and 90 µm in D. (Adapted from Spillantini et al., 1998). 
E) -G) Brain tissues from patients with DLB immunostained for αSyn. αSyn-
immunoreactive LBs and Lewy neurites in hippocampus (E) and substantia nigra (F 
and G). Scale bars are equivalent to 80 µm in E, 100 µm in F and 40 µm in G. 




1.4.2 SNCA Point mutation cases 
In the last 20 years, several missense mutations in the SNCA gene have been identified 
(Table 1.1). The A53T, A30P and E46K missense mutations were identified first, and are 
well recognized to cause rare forms of autosomal dominant inherited PD (Kruger et al., 
1998; Polymeropoulos et al., 1997; Zarranz et al., 2004). 
The first mutation, A53T, was identified in two large kindreds descending from the same 
ancestors in Italy, and in three Greek kindreds (Polymeropoulos et al., 1997). A single 
nucleotide substitution at position 209 from G to A results in amino acid change from 
alanine to threonine at amino acid residue 53. The mutation segregates with PD phenotypes 
with 85% penetrance. Patients with this mutation had clinical features similar to sporadic PD 
except with an early age of onset (average 46 years), and a rapid disease progression 
(Polymeropoulos et al., 1997).   
A year later, the A30P mutation was identified in a family of German origin (Kruger et al., 
1998). The average disease age onset caused by the mutation (59.7 years) is slightly younger 
than idiopathic PD, but with a similar rate of progression, suggesting a milder phenotype 
than the A53T mutation (Kruger et al., 2001; Kruger et al., 1998). 
Unlike the first two mutations, the E46K mutation causes phenotypes resemble DLB except 
that dementia develops in two or more years after disease onset (Zarranz et al., 2004).  The 
affected individuals manifested parkinsonism, dementia, and visual hallucinations of 
variable severity. Postmortem examination revealed atrophy of the substantial nigral and 
numerous LBs in cortical and subcortical area, which is consistent with DLB (Zarranz et al., 
2004). 
Other recently identified mutations include H50Q, G51D and A53E mutations (Appel-
Cresswell et al., 2013; Kiely et al., 2013; Lesage et al., 2013; Pasanen et al., 2014; Proukakis 
et al., 2013) (Table 1.1). The mutations caused rare forms of hereditary autosomal dominant 
PD.   
Animal models have confirmed the toxicity of the A53T, A30P, and E46K mutations as 
reviewed by Dawson T. et al. (Dawson et al., 2010).  Moreover, in vitro studies 
demonstrated that the mutations cause secondary structural changes and altered 
physicochemical properties of the protein.  For example, the A53T mutation accelerates  
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Table 1.1 Clinical and pathological characteristics of familial PD caused by missense mutations of SNCA. (Adapted from Fujioka et al., 2014). 
AAO, age at onset; MDD, mean disease duration; LB, Lewy body; MSA, Multiple system atrophy; GCIs, glial cytoplasmic inclusions 
aUncommon in sporadic PD.
Mutation AAO/MDD (years) Clinical phenotype Pathology Reference 
A30P 54–76 
PD (sustained response to L-dopa therapy), hallucinationa 
LB, Tau  
Krüger et al. 1998, Krüger et al. 
2001 
E46K 50–69 PD, cognitive impairment, visual hallucination
a, REM 
sleep behaviour disorder 
LB Zarranz et al. 2004 
H50Q 60–71/12 PD, cognitive impairment, psychiatric symptoms LB, Tau 
Appel-Cresswell et al. 2013, 
Proukakis et al. 2013 




Lesage et al. 2013, Kiely et al. 2013 
A53E 32-62/ 24 Atypical PD (early-onset), MSA, profound spasticity, 
myoclonic jerks, anxiety, panic disorder 
LB , TDP-43, 
GCIs 
Pasanen et al. 2014 
A53T 20–85/12 PD (early-onset, rapidly progressive), dementia, 
dysautonomiaa, myoclonusa, psychiatric symptomsa 
LB , Tau , 
TDP-43 




fibril formation of the protein in vitro (Conway et al., 2000b). Unlike A53T, the A30P αSyn 
mutant has a slower fibrillization rate but exhibits rapid formation of spherical oligomers 
(Conway et al., 2000a). These structural alterations would interfere with normal 
physiological functions of the protein as well as confer gain-of-function toxicity. 
1.4.3 SNCA Multiplication cases 
In 1998, Muenter et al. described the pathological and clinical characteristics of the 
autosomal dominant hereditary parkinsonism with dementia in a family known as “the Iowa 
kindred” (Muenter et al., 1998). This hereditary PD is markedly characterised by severe 
parkinsonism, very young age onset, rapid disease progression and dementia. 
Neuropathological examination revealed profound pathology including severe degeneration 
of the substantia nigra, of which one autopsy had more that 90% nerve cell loss, wide spread 
occurrence of subcortical and cortical LBs, vacuolation of the cortex in the temporal lobe, 
and unusual nerve cell loss in the hippocampus. Five years later, Singleton and colleagues 
demonstrated co-segregation of heterozygous SNCA triplication with parkinsonism in 
affected members in this family (Singleton et al., 2003). Expression of all four SNCA alleles 
resulted in a doubling in amount of α-syuclein protein and mRNA in blood and brain of the 
affected members (Farrer et al., 2004; Miller et al., 2004). One year later, SNCA triplication 
was reported in an unrelated Swedish-American descent family with comparable 
neuropathology and clinical features to that of the Iowa kindred (Farrer et al., 2004). Early 
ages of disease onset, dementia and cornu ammonis 2/3 hippocampal degeneration were 
common features of this form of PD (Farrer et al., 2004). 
Ibáñez et al. identified SNCA heterozygous duplication in two PD patients with familial 
history of PD (Ibanez et al., 2004). Compared to the triplication cases, these patients had 
later ages of disease onset (46 and 56 years), subtle clinical features, such as mild 
parkinsonism and mental impairment without any atypical symptoms. Disease progression is 
slow considering that their mothers, who were also reported to have parkinsonism, survived 
until the age of 80 years.  
These observations suggested that clinical features might be influenced by the SNCA gene 
dosage; the more SNCA alleles, the more severe symptoms would be. Nonetheless, there was 
a concern of whether SNCA was indeed a causative gene of the disease phenotype.  In other 
words, the phenotype severity might depend on other genes within the multiplied region. 
Regarding this concern, there is a report on a family with SNCA duplication, of which the 
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multiplication region contains no other genes but SNCA.  PD in this family is autosomal 
dominant inherited, and has phenotype similar to idiopathic PD. This finding proved that 
multiple copies of SNCA alone can cause PD (Ibanez et al., 2009). 
To investigate the relationship between SNCA dosage and clinical severity, direct 
comparison of the disease manifestation between affected families was difficult in early time 
due to variation in genetic background and multiplication region. However, when more cases 
of familial SNCA multiplication were reported, the notion of SNCA dosage effect on disease 
phenotypes appeared to be true. Fuchs et al. investigated clinical phenotype of a carrier of 
SNCA triplication and that of SNCA duplication, all carriers shared the same region of 
genetic multiplication (Fuchs et al., 2007). The probands were from two kindreds that were 
inherited the multiplied genetic region from a common ancestor known as the “Lister family 
complex”. As expected, a proband with SNCA triplication had more severe clinical features 
than that with duplication.  
Similar to the Lister family complex descents, SNCA gene dosage effect was demonstrated in 
a large Japanese family, of which the members carried heterozygous SNCA duplication (3 
alleles of SNCA) or homozygous SNCA duplication (4 alleles of SNCA) (Ikeuchi et al., 
2008). Gene multiplication this family occurred within the same genetic region due to 
consanguineous marriage. The proband with homozygous SNCA duplication showed similar 
clinical manifestations to that of SNCA triplication, and manifested more pronounce 
phenotypes than the heterozygous probands.  
Moreover, disease penetrance caused by SNCA triplication is clearly higher than that caused 
by duplication (85% vs 33-50%) indicating increased aggressiveness of SNCA triplication 
compared to SNCA duplication (Muenter et al., 1998; Nishioka et al., 2009). 
Genetic background and environmental factors are likely to have considerable contribution 
to the phenotype of this form of PD (Nishioka et al., 2009). In SNCA duplication cases, 
clinical manifestations variable between the carriers including no symptoms, parkinsonism, 
MSA, PDD, and DLB (Fuchs et al., 2007; Ibanez et al., 2009; Nishioka et al., 2009; 
Uchiyama et al., 2008). Some SNCA duplication carriers did not show any sign of 
parkinsonism despites their ages were beyond the mean age of disease onset (Ibanez et al., 
2009; Nishioka et al., 2009). Ages of disease onset are also considerably variable among 
affected individuals (Ibanez et al., 2009). The number of genes in genetic multiplied region 
or the size of multiplication is unlikely to correlate to the age of disease onset as two 
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asymptomatic individuals were identified in a family, of which duplication region was 
estimated to contain 23-25 genes within a region of approximately 3.5 Mb (Ibanez et al., 
2009).   
1.4.4 Effect of αSyn on cellular ROS production 
Oxidative stress is an imbalance state of ROS production and cellular detoxification (Dias et 
al., 2013). When the level of ROS is beyond the ability of cell to cope with, the cell is under 
oxidative stress. Oxidative stress could lead to damage to cellular components. Moreover, 
feed-forward scenarios could happen when the damage occurs to a key cellular pathogenic 
protein that in turn causes more ROS production (Dias et al., 2013).  
The link of oxidative stress and neurodegeneration is suggested by the evidence of oxidative 
damages in the SNs of PD patients. These damages include the increase in amount of lipid 
peroxidation (Floor and Wetzel, 1998), protein oxidation (Alam et al., 1997; Floor and 
Wetzel, 1998), and nucleic acid damage (Zhang et al., 1999).  
ROS and αSyn aggregation have impacts on each other; aggregated αSyn increases ROS 
production, and ROS exacerbates αSyn aggregation. This could happen through a feed-
forward mechanism, which eventually could result in more ROS production and α-increased 
susceptibility of cells to oxidative stress (Dias et al., 2013). In vitro, aggregation of αSyn can 
be induced by oxidative reactions (Hashimoto et al., 1999; Paxinou et al., 2001), and adding 
of antioxidants eliminates the inhibitory effect of catecholamine on fibril formation (Conway 
et al., 2001). On the other hand, overexpression of WT αSyn or its mutant resulted in 
increased intracellular ROS level (Junn and Mouradian, 2002; Parihar et al., 2009) and cell 
susceptibility to oxidative stress (Jiang et al., 2007). Transgenic mice expressing A30P 
mutant exhibited increased protein carbonyl, a marker for protein oxidation (Poon et al., 
2005).  
Several cellular processes have been implicated in ROS production (Dias et al., 2013), of 
which mitochondria has a close relationship with αSyn and PD etiology. A significant 
mitochondrial accumulation of αSyn is observed in substantia nigra pars compacta and 
striatum of PD patient, compared to healthy age-matched controls (Devi et al., 2008b).  
Neurons are highly active cells containing large number of mitochondria to provide ATP by 
oxidative phosphorylation. Impaired components of the electron transporter chain may cause 
leakage of electrons to oxygen, resulting in a production of superoxide anion, which is a 
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precursor of most other ROS (Turrens, 2003). The protein αSyn has an inhibitory effect on 
complex I activity. Reduced complex I activity by αSyn was observed in cell culture (Devi et 
al., 2008a; Loeb et al., 2010) and transgenic animals (Liu et al., 2009a). These observations 
are consistent with the decrease in complex I activity observed in PD brain samples (Devi et 
al., 2008a; Parker et al., 2008).  
Apart from direct inhibition of complex I, oxidative phosphorylation may be impaired as a 
consequence of mitochondrial dysfunction induced by αSyn (Protter et al., 2012).  αSyn 
could induce mitochondria dysfunction by  perturbing mitochondrial fission-fusion cycle 
(Kamp et al., 2010; Nakamura et al., 2011), inhibiting of autophagy and mitophagy 
(Winslow et al., 2010), blocking endoplasmic reticulum-Golgi traffic (Porte et al., 2006). As 
these cellular processes are essential to maintain homeostasis and functionality of 
mitochondria, perturbing the processes could result in mitochondrial dysfunction. 
Interestingly, in addition to being a causative agent of mitochondrial dysfunction, αSyn can 
be affected by mitochondria. Inclusion or aggregation of αSyn was induced by mitochondria-
disrupting drugs, rotenone and MPTP, in mouse and cell models (Fornai et al., 2005; Lee et 
al., 2002). The interplay between mitochondrial dysfunction, ROS and αSyn misfolding is 
complicated and it is unclear which one may be the cause or consequence. αSyn could be a 
cause by impairing the mitochondrial respiratory chain, which results in increased ROS 
production. Alternatively, αSyn may become oxidised and aggregated by increased ROS as a 
result of mitochondrial dysfunction (Nakamura, 2013). 
1.5 Random insertional transgenesis of hES cells using plasmid vectors 
hES cells are pluripotent cell lines isolated from the ICM of blastocysts (Thomson et al., 
1998). Their capacity to differentiate in vitro into various cell types in the body holds great 
promise to regenerative medicine, and represents an experimental resource to study 
developmental biology and disease modelling. The application potential of hESC lines has 
been accelerated by their amenableness to genetic modification without losing pluripotency. 
For instance, transgenic hESC reporter lines can be used to identify hESC derivatives during 
differentiation, allowing purification of the target cells or understanding the functions of the 
gene of interest during hESC differentiation. 
Among several genetic modification approaches, random integration of transgenes into the 
genome of hES cells is one of the most commonly used methods, especially, for 
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overexpression of genes. This strategy is based on a natural cellular process that employs 
endogenous DNA-modifying machinery to incorporate exogenous DNA into the 
chromosomal DNA of the host cells (Wurtele et al., 2003). As it is not site-targeted, DNA 
insertion can occur more than once at various chromosomal sites, which could result in 
multiple copy number of the transgenes to integrate per cell. This advantage enables 
scientists to generate clonal lines that differ in transgene expression level, which are useful 
generating an allelic series to study the effect of the gene at different doses. 
The disadvantages of random insertional transgenesis include: (i) DNA integration into a 
chromosomal site that is less accessible by transcription factors, which can lead to silencing 
or reduced expression of the transgene, (ii) random DNA integration may interrupt the 
expression of endogenous genes or cause structural changes, which could affect the stability 
of the genome (Wurtele et al., 2003). As these effects may influence cell phenotype, 
screening and analysis of multiple clonal lines during hESC propagation and differentiation 
should be rigorously performed.  
There are two platforms for gene delivery, viral transduction and transfection of plasmid 
DNA. Viral delivery of genes is normally highly efficient. If retroviruses are used then DNA 
is not integrated into the genome, which can cause problems with the longevity of the effect. 
Lentiviruses integrate into the genome, ensuring longevity of the effect, but then can cause 
other effects due to integration of parts of the viral genome. Methods exist to try and ensure 
that viral genome is not left in the host genome. The plasmid platform gives lower 
transfection efficiency and survival rate (Cao et al., 2010); however the method allows rapid 
transfection with a relatively simple and straightforward preparation process. Indeed, 
transfection efficiency and survival rate of hES cells is mainly dependent on transfection 
method. A comparison of gene delivery via electroporation, nucleofection and chemical 
transfection reagent revealed that nucleofection provided the highest transfection efficiency 
(5.8-6.1%) with modest survival rate (Cao et al., 2010). The electroporation and 
Lipofectamine transfection methods gave relatively low transfection efficiency (1.9-2.1% 
and 1.3-1.5%, respectively). Of these, electroporation gave the poorest cell survival. Low 
survival rate during nucleofection or electroporation is due to dissociated hES cells in single-
cell suspension. Treatment with an inhibitor of Rho-associated kinase (ROCK) inhibitor, 
such as Y-27632, significantly improved the survival rate of dissociated hES cells 
(Watanabe et al., 2007). Alternatively, electroporation in clumps can also increase hESC 
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viability; however, this will result in multi-cell non-clonal lines (Zwaka and Thomson, 
2003).  
One of the most important parts of transgenesis is plasmid design. Besides a transgene of 
interest, two major components of an expression plasmid include a promoter to drive 
transgene expression, and a selectable marker. A selectable marker allows selection of stably 
transfected clones whereas the promoter determines the level and pattern of transgene 
expression. Liew et al. demonstrated that the choice of promoter and expression cassette are 
critical factors for establishing stable hESC lines (Liew et al., 2007). The authors compared 
four different promoters in driving eGFP expression in hES cells, and found that pUbiC, 
pR26, pCAGG are more superior to the pCMV for generation of stable transfectants. 
Additionally, long-term culture of these eGFP-expressing hESC clones lead to gene 
silencing, which could be prevented by combining a promoter with another regulatory 
element, more specifically in this study, pCAGG with PyF101 Polyoma Enhancer. The 
pCAGG promoter is commonly used for stable, constitutive expression during both ES cell 
propagation and differentiation. The functional stability of pCAGG has been demonstrated in 
driving eGFP expression in transgenic mice produced by germ transmission of transgenic 
eGFP mouse embryonic stem (mES) cells (Hadjantonakis et al., 1998). Some transgenic 
mES cell line clones stably maintained ubiquitous fluorescence expression during ES cell 
culture, in vitro differentiation, and in vivo when the mES cells were used to make chimeric 
mice. The pCAGG promoter also has been applied successfully in hES cells. Ectopic 
expression of SOX17 or SOX7 in hES cells followed by in vitro differentiation allowed 
establishment of stable endoderm progenitors that can be maintained stably in culture 
(Seguin et al., 2008). 
1.6 Neural differentiation of hES cells 
Neural differentiation of hES cells employs activation and inhibition of defined 
developmentally-relevant signalling pathways to dictate the fate of cells. Generally, directed 
hESC differentiation into specific neuronal subtypes has two stages: 1. Neural induction of 
the pluripotent stem cells and 2. Directed neuronal subtype specification.  
1.6.1 Neural induction  
Traditional protocols for neural induction include embryoid body (EB) formation and co-
culture with stromal cell lines. These methods benefit from enabling simple and low-cost 
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differentiation; however, the results can be variable. The EB-based protocol often produces 
heterogeneous cell populations, and the differentiation is difficult to control due to the 3-
dimentional structure of the aggregates. With the co-culture methods, the interaction 
between stromal cells and ES cells is poorly defined and are difficult to control and 
manipulate.  
Recent advances in protocols for neural induction are based on an adherent, monolayer 
culture protocol known as “dual-SMAD inhibition” (Chambers et al., 2009). With this 
protocol, hES cells are differentiated while growing as a monolayer on a feeder-free 
basement matrix (Figure 1.4A). Neural induction is achieved by the synergistic action of two 
inhibitors of SMAD signalling, a bone morphogenetic protein (BMP) inhibitor and an 
Activin/Nodal inhibitor. The protocol used recombinant human Noggin to inhibit BMP 
signalling and the chemical antagonist, SB431542, to inhibit Activin/Nodal signalling and 
achieved 80% of neural induction efficiency after 11 days of differentiation (Chambers at 
al., 2009).  The resulting neuroepithelial cells default to a forebrain identity, expressing 
PAX6, OTX2 and FOXG1 (Figure 1.4), and are patternable to neuronal subtypes, such as 
dopaminergic neurons and motor neurons (Chambers et al., 2009).  
SB431542 is an antagonist of type I receptors of Nodal/Activin/TGFβ signalling (Inman et 
al., 2002), which play a role in maintaining pluripotency of hES cells (James et al., 2005). 
Noggin is a BMP inhibitor, blocking BMP signalling by direct interacts with BMPs at the 
receptor binding sites (Groppe et al., 2002). In Xenopus, Noggin is secreted from Spemann’s 
organizer, and induces neural tissue from dorsal ectoderm (Lamb et al., 1993). Chambers et 
al. observed a synergistic effect of these two inhibitors on hESC neural induction.  
Combined treatment yielded great neural induction efficiency with 80% PAX6+ cells 
compared to 10% when Noggin or SB431542 were used alone. The results suggested that 
Noggin and SB431542 worked synergistically on multiple stages of differentiation including 
destabilizing the pluripotency network and suppression of alternative embryonic lineages 
induced by BMP and nodal/activin/TGFβ signalling.  
The dual-SMAD inhibition protocol in monolayer format enables cells to be exposed to 
nutrients and exogenous factors in the medium evenly. As a result, neural differentiation of 
hES cells is effective, robust, and with a high degree of homogeneity. Using chemically 
defined medium and exogenous factors makes the differentiation controllable. A recent 
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modified protocol employed a chemical BMP receptor antagonist, LDN-193189, in place of 
Noggin; thus lower the cost of differentiation (Chambers et al., 2012).  
 
Figure 1.4 Neural induction of  hES cells by dual-SMAD inhibition. (Adapted from 
Chambers et al., 2009).  
A) Immunustain for OCT4 and PAX6 of neuralised hES cells at Day 1, Day 3, Day 
5 and Day 7 of neural induction. The hES cells were neuralised by dual-SMAD 
inhibition. By Day 7 of differentiation, the protocol yields PAX6+ neuroepithelial 
cells.  
B) Day 11-neural induced cells immunostained for PAX6, OTX2 and FOXG1. At 
Day 11 of differentiation, the neuroepithelial cells express PAX6, OTX2 and 
FOXG1, transcription factors characteristic of anterior CNS.  





1.6.2 Directed differentiation towards cortical neurons 
Shi et al. reported a protocol of directed differentiation of human pluripotent stem cells 
towards cortical projection neurons under a feeder-free, adherent culture condition (Shi et 
al., 2012). The protocol consisted of: 1. cortical neural induction, and 2. genesis and terminal 
differentiation of cortical projection neurons. 
Cortical neural induction  
Employing dual-SMAD inhibition and retinoid signalling, neural induction produced a 
population of neuroepithelial cells with anterior CNS character as indicated by the 
expression of PAX6, FOXG1 and OTX1/2 (Figure 1.5A-B). Three known populations of 
cortical stem and progenitor cells were identified in the rosettes, the ventricular zone 
epithelial cells or radial glia cells, the basal progenitor cells and the outer radial glia (oRG) 
cells. Of these, the radial glia cells, characterized by radial processes and PAX6+, OTX+ and 
Ki67+, account for the majority of the population. The authors also showed that retinoid 
signalling, vitamin A and it derivatives added as a component of B27, was essential for 
efficient cortical neural induction. With retinoic acid, almost all of the cells are PAX6+ after 
15 days of differentiation, compared to 25% when retinoic acid was not applied.  
Genesis and terminal differentiation of cortical projection neurons 
Similar to cortical genesis in vivo, it took almost three months following neural induction to 
generate all classes of cortical projection neurons using this protocol. Immunostaining for 
transcription factors specific to different cortical layers revealed that neurogenesis occurred 
in a temporal order, in which deep layer neurons were generated before those in upper 
layers. The early born neurons were Tbr1+ (layer VI), which appeared within the first week 
of FGF2 withdrawal. And several weeks later (between days 65 and 80), the neurons layers 
II-III-IV, which express Satb2, were produced (Figure 1.5). 
The neurons developed maturity overtime in culture. As early as day 28 of differentiation, 
the neurons were electrophysiological excitable with a single firing of action potential in 
response to step current. And by day 65, firing of a train of action potentials was detected in 
many neurons. Additionally, the neurons acquired functional excitatory glutamatergic 




Figure 1.5 Directed differentiation of hES cells into cortical neurons. (Adapted from Shi 
et al., 2012). 
A) - B) Neural induction of hES cells via dual-SMAD inhibition in the presence of retinoids 
results in neural rosettes comprising of neural stem and progenitor cells with cortical 
identity. FGF2 allows cells to propagate and remain in this stage whereas withdrawal 
leads to further differentiation and genesis classes of cortical neurons.  
C) - E) Deeper-layer neurons are identified by expression of Tbr1 and/or CTIP2. White 
arrows indicate CTIP2+, Tbr1- neurons, which are corresponding to corticospinal motor 
neurons of layer 5. 
F) -H) Upper-layer neurons are identified by expression of Cux1, Satb2 and Brn2.  
I) Diagram shows classes of cortical projection neurons in adult mouse brain, with 
transcription factors indicated.  
J)  Time-course quantitative analysis of subsets of cortical neurons derived from hES cells 
showed that deeper-layer neurons (Tbr1+ or CTIP2+) were produced before those in 
upper-layers.  
Scale bars are equivalent to 50 µm. 
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Chapter 2  
Materials and Methods 
 
2.1 Materials 
2.1.1 Cell lines 
Shef4 hESC line 
The Shef4 hESC line was kindly provided by Dr. David Hay (University of Edinburgh), 
upon MRC Steering Committee approval (ref. no. SCSC11-60). The line was established at 
the Centre for Stem Cell Biology at the University of Sheffield under a license from the 
Human Fertilisation and Embryology Authority (HFEA), and has been validated to show the 
standard hESC characteristics including a normal karyotype (Aflatoonian et al., 2010). 
Human iPS cell lines 
Two human iPS cell lines, NAS2 and AST18, were established using Yamanaka retroviruses 
and fully characterised within the lab (Devine et al., 2011).  
SNL feeder cells 
The SNL cell line is available from European Collection of Cell Cultures, ECACC. It is a 
derivative of STO feeders with a G418-restance transgene to constitutive express LIF 
(McMahon and Bradley, 1990).  
2.1.2 Plasmid DNA 
The cDNA3.1 plasmid containing WT-human SNCA was provided as a generous gift from 
Professor John Hardy, UCL Institute of Neurology, UK. FCT-IVpBS and PGK-Puro-pCAG-
stuffer, sources of IRES-Venus and pCAG backbone, respectively, were kindly provided by 
William Hamilton, a former PhD student in the Kunath lab.  pCAG-GFP was kindly 
provided by Agnieszka Paca, a former PhD student in the Kunath lab.   
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2.1.3 Media for molecular cloning 
LB broth 
An amount of 25 g of DifcoTM LB Broth powder (BD, 244620) was dissolved in deionised 
water and sterilised by autoclaving. The medium was stored at 4C to use within 4 weeks.  
Prior to use, 100 µg/ ml ampicillin was freshly added. 
LB  agar (500 ml) 
To produce 15% LB agar, unsterilized LB broth was added with 15% DifcoTM LB agar and 
sterilised by autoclaving. When the medium was cooled down to 50C, 100 µg / ml 
ampicillin was added and mixed thoroughly.  The medium was poured into ½ volume of 10-
cm polystyrene Petri dishes and allowed to solidify at room temperature for at least one hour. 
The agar plates were stored at 4C to use within 4 weeks. 
2.1.4 Media used for tissue culture 
HESC medium 
KnockOut™ DMEM/ F-12 (Gibco, Cat. no. 12660-012) supplemented with 20% KSR 1X 
non-essential amino acids (Gibco, Cat. no. 1140-035), 2 mM L-glutamine (Invitrogen, Cat. 
no. 25030-024), 50 mM 2-mercaptoethanol (BDH, Cat. no. 44143-31), 100 U/ml penicillin, 
100 µg/ml streptomycin (Invitrogen, Cat. no. 15140-122) and 20 µg/ml FGF2 (Peprotech, 
Cat. No. 100-18B). 
mTeSR1 medium 
The two components of the medium including mTeSR™1 Basal Medium (400 mL) (Catalog 
no. 05851) and mTeSR™1 5X Supplement (100 mL) (Catalog #05852) was mixed, and then 
dispensed into 50 ml tubes. The aliquots were stored in -20 C and used within 4 weeks after 




GMEM (Sigma, Cat. no. G5154) supplemented with 10% FCS (Invitrogen, Cat. no.10270), 
2 mM L-glutamine (Invitrogen, Cat. no. 25030-024), 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen, Cat. no. 15140-122). 
N2B27 (200ml)  
N2B27 was prepared by mixing: 98 ml DMEM/F12 (Gibco, Cat. no. 20331-020), 98 ml 
Neurobasal medium (Gibco, Cat. no. 21103-049), 1ml N2 supplement, 2 ml B27 with 
retinoic acid (Gibco, Cat. no. 17504-044). In addition, 2 mM L-glutamine, 0.1 mM β-
mercaptoethanol (BDH, Cat. no. 44143-31), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Invitrogen, Cat. no. 15140-122) were added. 
3N medium 
3N medium is N2B27 supplemented with 100 μM non-essential amino acids (Gibco, Cat. no. 
1140-035). 
DAP213 
The hES cell freezing medium was prepared by mixing: 5.37 ml hES medium, 1.43 ml 
DMSO, 1.0 ml acetamide and 2.2 ml propylene glycol. The solution was aliquoted in 1.5 ml 
Eppendorf tubes and stored at -80 C to be used within 1 month after preparation. 
 
2.2 Methods  
2.2.1 Molecular cloning 
Polymerase chain reaction and purification of PCR products 
Amplification of IRES-Venus or SNCA fragments were performed in 200 l tubes using 
PCR machine (MJ Research, PTC-200 Peltier Thermal Cycler). A 50 µl PCR reaction 
includes 1x PCR Pfx amplification buffer, 1 mM MgSO4, 1 unit Platinum® Pfx polymerase 
(all from Invitrogen, Cat. no. 11708-013), 1 mM of each dNTPs, 1 pmol/μl of forward 
primer, 1 pmol/μl of reverse primer, 1 ng template DNA and RNase/DNase free water.  
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All primers are available in Table 2.1. Resulting PCR was analysed for product size by 
electrophoresis using 0.8% agarose gel (Invitrogen, Cat. no. 16500-100) in 1XTAE buffer at 
80 volts for 1 hour using 1 kb DNA ladder (Invitrogen, Cat. no. 15615-016) as DNA marker. 
After PCR product size had been verified, PCR product was purified using DNA Clean & 
Concentrator™-5 Kit (Zymo Research, Cat. no. D4003) resulting in 20 µl of eluted DNA, 
which would be enzymatic digested in later steps.  
DNA digestion 
A total volume of 25 µl digestion reaction is consisted of 600 ng backbone plasmid vector or 
20 l of purified PCR product, 1X bovine serum albumin, 1X digestion buffer and 50 U 
digestion enzyme (all from New England Biolabs® Inc). The reaction was incubated at 37C 
for 1.5 hour. Only for the digested DNA vector, 0.5 l of CIP (New England Biolabs® Inc, 
Cat. no. M0290S) was added into the digestion reaction followed by incubation at 37C for 
20 minutes.  Subsequently, the reaction was heat-inactivated at 65C for 20 min. Along with 
1 kb DNA ladder (Invitrogen, Cat. no. 15615-016), digested DNA sample was 
electrophoresed in 0.8% agarose gel in 1XTAE at 80 volts for 1 hour. 
DNA isolation from agarose gel  
Enzymatic digested DNA was purified from agarose gel using Zymoclean™ Gel DNA 
Recovery Kit (Zymo Research, Cat. no. D4001) following manufacturer’s protocol. In the 
final step, 20 l of DNAse-free water was added to the column matrix to elute DNA. DNA 
concentration was measured using NanoDrop 2000 Spectrophotometer (Thermo Scientific) 
before use. 
DNA ligation 
Purified, digested DNA was ligated in a final volume of 20 l using 2 U of T4 DNA ligase 
and 1x ligation buffer (all from Roche, Cat. no. 10481220001).  The amount of vector DNA 
and DNA insert was used at 1:3 or 1:6 molar ratio of vector to insert. The ligation reaction 
was performed at 16C overnight. 
 
 
Table 2.1 Primer sequences for PCR or qPCR.








NVEN-F TATTCGCGGCCGCAGTACTCCCTCTCAAAAGCGG - 
















Transformation of plasmids into competent E. coli  
Plasmid DNA was transformed into TOP10 chemically competent cells (Invitrogen, Cat. no. 
c4040-10) or home-made E. coli DH5α competent cells (see below) by the heat-shock 
method. Firstly, plasmid DNA and a vial of competent cells were thawed on ice. Once 
thawed, 1.0 to 1.3 ng of plasmid DNA was gently mixed with the competent cells in the vial, 
and then incubated on ice for 5 minutes. To heat-shock, cells were incubated in a 42°C 
water-bath for 45 seconds prior to placing on ice immediately for 5 minutes. To recover 
bacterial cells, a volume of 250 µl of pre-warmed (37°C) SOC medium (Invitrogen™, Cat. 
no. 15544-034) was added into the vial followed by incubation at 37°C with constantly 
shaking for 45 minutes. A volumes of 20 µl and 100 µl of cell suspension were spread onto 
two LB agar plates containing 100 µg/ml ampicillin. In an effort to recover all transformants, 
the rest of cell suspension was centrifuged, and then, following supernatant removal, cells 
were plated on another antibiotic-containing agar plate.  Plates were then incubated at 37°C 
for 13-15 hours and colonies were picked and expanded for plasmid extraction.  
Minipreps of E.coli cultures 
Plasmid DNA was extracted using QIAprep®-Spin Miniprep kit (Qiagen, Cat no. 27104) 
following the manufacturer’s protocol. Briefly, bacterial cell pellet was re-suspended with 
250 l of buffer P1 in a 1.5 ml Eppendorf tube. Then, cells were lysed with 250 µl of buffer 
P2 followed by inverting the tube to mix thoroughly. Next, 350 l of buffer N3 was added to 
each tube, and mixed well. To separate DNA from cell debris, the lysate was centrifuged at 
13,000 rpm (Eppendorf, Centrifuge 5415 C) for 10 minutes, and the supernatant was gently 
transferred into a clean QIAprep spin column. To isolate DNA from the supernatant, the 
column was centrifuged at 13,000 rpm for 10 min, and the resulting filtrate was discarded. 
To wash DNA, 750 µl of buffer PE was applied into the column followed by centrifugation 
at 13,000 rpm for 1 minute.  After filtrate has been discarded, the column was centrifuged 
again to remove residual washing buffer. Then the column was transferred into a new, clean 
Eppendorf tube, and 20-50 µl of buffer EB was subsequently applied to the column. DNA 
was eluted by centrifugation at 13,000 rpm for 1 min. DNA concentration was measured 






Maxipreps of E.coli cultures 
DNA extraction was performed using QIAGEN plasmid Maxi Kit based on the 
manufacturer’s protocol (Qiagen, Cat. no. 12662). In a 50-ml Corning tube, bacterial pellets 
were re-suspended with 10 ml of buffer P1. To lyse cells, 10 ml of buffer P2 was added into 
each tube followed by vigorously inverting 4-6 times. Next, the mix was incubated at room 
temperature for 5 minutes, and then 10 ml of buffer P3 was applied. The tube was vigorously 
inverted for 4-6 times, and then incubated on ice for 20 minutes until lysed blue colour was 
gone and the suspension became colourless. To separate DNA from cell debris, cell lysate 
was centrifuged at 20,000 g for 30 minutes at 4C, and resulting supernatant was transferred 
into a new tube.  The supernatant was centrifuged again for 15 minutes to remove residual 
cell debris. During centrifugation, QIAGEN-tip was prepared by applying 10 ml of buffer 
QBT, and then the column was allowed to empty by gravity flow. Next, supernatant was 
applied in the QIAGEN-tip and allowed to enter the resin by gravity flow. Then, the 
QIAGEN-tip was washed twice by gravity flow with 30 ml Buffer QC. To elute DNA, the 
QIAGEN-tip was placed in a clean 50-ml corning tube, in which and 15 ml of buffer QF was 
subsequently added. Eluted DNA was precipitated with 10.5 ml of isopropanol followed by 
centrifugation at 15,000 g for 30 minutes at 4C. After supernatant removal, the DNA pellet 
was washed with 5 ml 70% ethanol followed by centrifugation at 15,000 g for 10 minutes. 
Supernatant was discarded and the tube was re-centrifuged to remove residual ethanol. 
Finally, the DNA pellet was air-dried for 10-15 minutes at room temperature. Finally, DNA 
was dissolved with 500 µl of EB buffer and stored at -80C. 
Desalting DNA for nucleofection of Shef4 hES cells 
Linearised plasmid DNA was desalted using Millipore centrifugal filter units (UFC503024 
24PK, Millipore). DNase-free water was added into an Eppendorf tube containing DNA to 
top up the volume to 500 l, and then desalting was performed following manufacturer’s 
protocol. DNA concentration was measured using the NanoDrop 2000 Spectrophotometer 
(Thermo Scientific), and DNA was used for transfection immediately or stored at -20C.   
Preparation of chemically-competent E. coli DH5α cells 
LB agar plate was streaked with E. coli DH5α and incubated at 37°C overnight. To grow 
starter culture, a single colony was inoculated in 3 ml LB medium and incubated at 37°C 
with shaking overnight. Next day, 1 ml of starter culture was added into a flask containing 
200 ml of LB medium following by incubation at 18°C until OD600 of the culture had 
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reached 0.3. Cells were harvested by centrifugation at 3,000g for 10 minutes at 4°C. 
Following supernatant removal, pellet was re-suspended in 10 ml of ice-cold CCMB80 
buffer (pH7.4) (10 mM KOAc at pH 7.0, 80 mM CaCl2, 20 mM MnCl2, and 10 mM MgCl2, 
10% glycerol) and incubated on ice for 20 minutes. Then cells were collected again by 
centrifugation at 3,000 g at 4°C for 10 minutes. The resulting pellet was re-suspended with 
10 ml of ice-cold CCMB80 buffer and incubated on ice for 10 minutes. To aliquot competent 
cells, cells were dispensed in Eppendorf tubes at 50 µl per tube and were further incubated 
on iced for 20 minutes. Finally, cells were snapped frozen on a mixture of dry ice and 
ethanol prior to storing at -80°C to use within 2-3 months. 
2.2.2 Cell culture 
Preparation of irradiated SNLs for hESC culture 
SNLs were cultured on 100-ml dishes coated with 0.1% gelatin (Sigma, Cat. no. G1890) in 
SNL medium at 37C in a humidified incubator in the presence of 5% CO2. Cells were fed 
daily until confluent or nearly confluent. Then cells were trypsinised (Invitrogen, Cat. no. 
15090-046) and harvested to a 15-ml universal tube and collected by centrifugation at 1,300 
rpm (Eppendorf 5702) for 3 minutes. Following supernatant removal, cells were washed 
with PBS (Sigma, Cat. no. D8537), spun again, and then the resulting pellet was 
subsequently re-suspended in PBS. Finally, cells were irradiated at 80 Gray, and then 
aliquoted at 4106 cells per vial in 0.5 ml of freezing medium before storing at -80C. A 
frozen vial of aliquoted-irradiated SNLs were hand-thawed and immediately transferred into 
a universal tube containing 9.5 ml of SNL medium (see section 2.1.4). Cells were 
centrifuged at 1,300 rpm (Eppendorf 5702) for 3 minutes, and then supernatant was 
aspirated. Resulting cell pellet was re-suspended in SNL medium and plated on a 100-ml 
dish coated with 0.1% gelatine in SNL medium. Cells were incubated at 37C in a 
humidified with 5% CO2 incubator overnight and will be used within 1-2 days after plating. 
Prior to plating hES cells, SNL medium was replaced with hESC medium (see section 2.1.4) 
and cells were incubated at 37C in a humidified with 5% CO2 incubator for at least 1 hour. 
Matrigel coated plates 
Growth-factor reduced Matrigel (BD, Cat. no. 356234) was thawed and aliquoted following 
manufacturer’s instructions. To prepare a Matrigel-coated plate, all procedures were 
performed in cold conditions to slow down Matrigel polymerisation. An aliquot of frozen 
Matrigel was thawed at 4°C, and then diluted at 1:36 in cold KnockOut™ DMEM/F-12 
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(Gibco, Cat. no.12660-012). Diluted Matrigel was dispensed into a pre-chilled multi-well 
plate and incubated at 4°C overnight or until use. Generally, the plates were used within 1 
week from the date of preparation. To use Matrigel coated plates, excess liquid Matrigel was 
aspirated and mTeSR1 was added into the wells. The plate was warmed in the incubator for 
10-15 minutes before used for plating cells. 
hES cell and iPS cell Culture 
hES cells were cultured on Matrigel-coated 6-well plates (BD, Cat. no. 356234)  in mTeSR1 
medium (StemcellTM Technologies, Cat. no.05850). Cells were fed daily by replacing spent 
medium with 1.5-2 ml of fresh medium per well. Cell passaging was performed 
approximately every 4 days, when cells have reached a confluency of 70%-80% or colonies 
started to grow too large. To passage cells, spent medium was removed, and then cells were 
rinsed once with KnockOut™ DMEM/F-12 (Gibco, Cat. no.12660-012). Cells were treated 
with dispase for 3-5 minutes at 37C in a humidified incubator at 5% CO2. After dispase 
removal, cells were rinsed with KnockOut™ DMEM/F-12 once prior to adding 2 ml of 
mTeSR1 medium into the well. Colonies were scored using 10-ml plastic pipette, and then 
the entire surface was scraped using a cell scraper (Costar, Cat. no.3010). Cells were 
repeatedly pipetted to adjust clump size, and then were plated on a new pre-warmed 
Matrigel-coated 6-well plate in mTeSR1 medium at 1:2 ratio to 1:4 ratio depending on the 
confluency of a passaged plate. The was moved back and forth in order to have a good 
repartition of cells, and were cultured at 37C in a humidified incubator at 5% CO2. 
Freezing and thawing of hES cells and iPS cells 
Cells were frozen using DAP213 medium. Firstly, hES cells were treated with 10 µM ROCK 
inhibitor (Ascent, Cat. no.Y27632) for 1 hour in the incubator. Then, spent medium was 
removed and cells were rinsed once with KnockOut™ DMEM/F-12. To detach cells, cells 
were treated with AccutaseTM (Gibco, Cat. no. A11105-01) for 10-15 minutes in the 
incubator. When colony detachment started to appear, AccutaseTM was aspirated and 
mTeSR1 (Stemcell TechnologiesTM, Cat. no. 05850) was added into the well. Cells were 
scraped using a cell scraper and subsequently transferred into a universal tube. Then cells 
were collected by centrifugation at 1,300 rpm (Eppendorf 5702) for 3 minutes. After 
supernatant removal, cell pellets were re-suspended with 250 µl of DAP213 medium.  
Cells were quickly transferred into a cryovial and immediately snap frozen in liquid 
nitrogen. Cells were immediately stored in liquid nitrogen for long-term storage. 
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At 1 hour prior to thawing hES cells, SNLs was prepared by replacing SNL media in SNL 
culture with mTeSR1 medium supplemented with 10 µM ROCK inhibitor (Y27632, Ascent). 
To thaw cells, a cryovial of frozen hES cells was taken from liquid nitrogen and place on dry 
ice immediately. Warm mTeSR1 medium (800 µl) was added to each vial to promptly dilute 
and thaw the DAP213-frozen cells by hand. As soon as completely thawed, cells were 
transferred into 10 ml of warm mTeSR1 in a universal tube. Cells were collected by 
centrifugation at 1,300 rpm for 3 minutes. Following supernatant removal, the cell pellet was 
gently resuspended in warm mTeSR1 containing 10 µM ROCK inhibitor (Y27632, Ascent), 
and then transferred to a previously prepared SNL plate. Cells were incubated at 37C in a 
humidified incubator at 5% CO2 and fed daily with mTeSR1 until ready to passage. 
2.2.3 Nucleofection of hES cells 
Nucleofection was performed using the Neon and reagent kit (Invitrogen, Cat. no. 
MPK5000) as follows. 
1. Preparation of Matrigel-coated plate  
1) Matrigel (BD) was removed from each well of previously prepared 
Matrigel-coated 6-well plate. 
2) A volume of 1.5 ml of MEF-conditioned medium (R&D systems, Cat. no. 
AR005) supplemented with LIF and 10 µM ROCK inhibitor (Y27632, 
Ascent) was added in to the wells. 
3) The plate was incubated at 37C in a humidified incubator at 5% CO2. 
2. Preparation of Shef4 hES cells 
1) Spent medium was removed from each well of a total 6 wells of a 6-well 
plate of hESC culture. 
2) Cells were rinsed with 2 ml of KnockOut™ DMEM/F-12 (Gibco, Cat. no. 
12660-012). 
3) Then 800 µl of trypsin was added into each well. The plate was incubated in 
the incubator for 2-3 minutes. Then cells were observed for sings of 
detachment under a microscope. 
4) When the edges of colonies start to detach, trysin was removed. Cells were 
rinsed gently with 2 ml of K/O DMEM. 
5) Following K/O DMEM removal, the volume of 2 ml of K/O DMEM 
supplemented with ROCK inhibitor (Y27632, Ascent) was added into each 
well of hESC culture. 
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6) The entire surface of cells culture was scraped using a cell scraper, and then 
cell suspension was transferred into a universal tube. 
7) Cell suspension (10 µl) was applied onto hematocytometer for cell count to 
calculate the volume to obtain 1.2×106 cells (for 0.2x106 cells/well 
subsequent plating). 
8) Cells were collected by centrifugation at 1,300 rpm for 3 minutes, and then 
supernatant was discarded. 
9) Cell pellet was re-suspended with 59.4 μl buffer R, and then was mixed 
with 6.6 µl of 500 ng of linearized plasmid DNA. 
3. Transfection of hES cells 
Transfection was performed with Neon™ Transfection System following 
manufacturer’s protocol. A volume of 10 µl of cells-DNA mix was electroporated for 
each reaction at 1050 V for 2 pulses with duration of 30 msec. Following 
electroporation, cells were plated on previously prepared Matrigel-coated 6-well 
plates containing warm mTeSR1medium supplemented with 10 µM ROCK inhibitor 
(Y27632, Ascent) (BD). The plate was placed in the incubator, in which it was moved 
back and forth to allow even dispersion of cells. Next day, cells were observed for 
fluorescence expression under a microscope, and then were fed daily with mTeSR1 
medium after 48 hours transfection.  
4. Clonal expansion and drug selection of transgenic Shef4 hES cells    
When colonies are formed, consisting of 50-100 cells, drug selection started by 
feeding cells daily with mTeSR1 medium supplemented with 1 µg/ ml puromycin for 
at least 2 weeks. To isolate clones, colonies were manually picked and transferred into 
a 12-well plate, and then into a 6-well plate to expand. To bank hESC clones, cells 
were frozen in DAP213 medium and stored in liquid nitrogen. 
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2.2.4 Transfection of hES cells using Lipofectamine® LTX 
Transfection was performed when hES cells were on MatriGel in mTeSR1 medium 
following a protocol developed by Ludovic Vallier (University of Cambridge, UK) as 
follows.  
Day 1: A well of a confluent 6-well plate of hES cells was splited into 6 to 18 wells 
(depending on how confluent the cells are. Resulting plated cells should have very 
low density). Cells were fed with mTeSR1 medium without antibiotics. 
Day 2: Cells were fed with mTeSR1 without antibiotics. 
Day 3: The spent mTeSR1 medium was replaced with OPTIMEM medium 
(Invitrogen, 519 085-026). The hESC colonies were transfected based on an 
Invitrogen protocol as follows. 
1) In an Eppendorf tube, the amount of 4 µg DNA was diluted in 500 µl of 
OPTIMEM medium. 
2) A volume of 4 µl of Plus reagent was added in the tube from step 1. 
3) The mix was incubated at room temperature for 5 minutes. 
4) Then12 µl of Lipofectamine® LTX (Invitrogen, A12621) was added 
into the tube from step 3.  
5) The mix was mixed thoroughly, and then was incubated at room 
temperature for 30 minutes. 
6) A volume of 500 µl of the DNA-Lipofectamine mix was added drop by 
drop into a well containing cells. The plate was moved back and forth in 
order to have a good distribution of the transfection mix. 
7) The plate was placed back in the incubator to allow incubation for 18-20 
hours. 
Day 4: The OPTIMEM medium was replaced with mTeSR1 (without antibiotics). 
Day 5: Drug selection was performed by replacing spent medium with mTeSR1 
supplemented with 1µg/ml Puromycin (Sigma, P8833). 




Day 20: Colonies were picked into 24-well plates coated with Matrigel (BD). Cells 
were fed daily with mTeSR1 supplemented with 1µg/ml Puromycin. When colonies 
grow large, each of them is transferred into a 12-well plate, and then into a 6-well 
plate to expand. To bank hESC clones, cells were frozen in DAP213 medium and 
stored in liquid nitrogen. 
2.2.5 RNA isolation from hES cells 
RNA was isolated using Trizol® reagent (Life Technologies, Cat. no.15596026) and further 
purified using Zymo-SpinTM Kit (Zymo Research, Cat. no. R1011) as follows. 
1. Harvesting hES cells 
1) When hES cells are on feeder-free conditions in a 6-well plate, spent 
medium was removed, and then hES cells were rinsed with K/O DMEM. 
2) The volume of 1.0 ml of QIAzol® Reagent was added into the well. The 
plate was agitated gently to allow cells to lyse for 1-2 minutes.  
3) Cell lysate was transferred into an RNase-free Eppendorf tube. The lysate 
was subjected to RNA isolation or snap frozen on the mixture of dry ice and 
ethanol before storing in -80°C for later RNA extraction. 
2. RNA isolation and purification 
1) Frozen cell lysate was thawed at room temperature. 
2) Then 200 µl of chloroform was added into the tube in step 1. The tube 
was securely capped, and then was vortexed vigorously for 30 seconds. 
The lysate was incubated at room temperature for 2-3 minutes. 
3) The lysate was centrifuged at 12,000 g for 15 minutes at 4°C. 
4) A volume of 200 µl of the upper, aqueous layer was transferred into a 
new DNase/RNase-free Eppendorf tube. 
5) Then 200 µl of chloroform was added into the tube in step 5 
6) The tube was centrifuged at 12, 000 g at 4°C for 20 minutes 
7) Then 120 µl of the upper phase was transferred into a new tube.  
8) A volume of 360 µl of RAD buffer was added in to the tube, and then it 
was mixed thoroughly. 
9) The mix in step 8 was transferred into a Zymo-SpinTM Column in a 
collection tube. 
10) The collection tube was centrifuged at 12,000g for 2 minutes. And then 
the flow-through was discarded. 
11) A volume of 400 µl RNA prep Buffer was added into the column. 
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12) The column was centrifuged at 12,000 g for 1 minute. Then the flow-
through was discarded. 
13) A volume of 800 µl of RNA wash buffer was added into the column. 
14) The column was centrifuged at 12,000 g for 30 minutes. Then the flow-
through was discarded. 
15) The column was subjected to Steps 13) and 14). 
16) The Zymo-SpinTM Column was centrifuged at 12, 000 g for 2 minute to 
ensure the complete removal of wash buffer. 
17) The Zymo-SpinTM Column was carefully removed from the tube, and 
then placed into a new DNase/RNase-free tube. 
18) A volume of 10 µl DNase/RNase-free water was added directly into the 
centre of the column matrix. Incubation was allowed at room 
temperature for 1 minute. 
19) The column was centrifuged at 10,000 g for 30 seconds to elute RNA 
from the matrix. 
20)  RNA samples were measured for concentration and purity,  and then 
store at -80°C. 
 
2.2.6 Neural induction of hES cells 
Neural induction was performed based on a previously published monolayer protocol 
(Chambers et al., 2009) with slight modifications (Figure 4.1). hES cells were dissociated 
into single cells with Accutase (Gibco, Cat. no. A11105-01) and plated on a Matrigel-coated 
6-well plate in mTeSR1 medium. Cells were fed daily until they reached 90% confluency or 
above. Neural induction started at day 0, when mTeSR1 was replaced with hESC medium 
lacking FGF2, supplemented with 10 µM SB431542 (Tocris) and 100 nM LDN-193189 
(Stemgent, Cat. no. 04-0019). Cells were fed daily with this medium until day 4. From day 5 
to day 11, SB431542 was withdrawn and cells were fed every other day with a mixture of 
hESC medium and N2B27, which was gradually added into culture medium from 25%, 50%, 
75% and 100% at day 5, day 7, day 9 and day 11, respectively.  
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2.2.7 Directed differentiation towards cortical neurons 
To generate cortical neurons, human pluripotent stem cells were processed based on a 
protocol described previously (Shi et al., 2012). Briefly, cells were plated as single cells on a 
Matrigel-coated 6-well plate in mTeSR1 medium and allow to grow until nearly confluent. 
Neural induction started at day 0, when cells were fed daily for 11 days with 3N medium (in 
2.1.2) supplemented with 10 µM SB431542 (Tocris) and 100 nM LDN-193189 (Stemgent). 
To expand neural progenitors and stem cells, at day12, cells were dissociated into small 
clumps with dispase, and then plated on laminin/poly-L-ornithine-coated plates (see section 
2.2.7) in 3N medium supplemented with 100 nM LDN-193189 and 20µg/ml FGF2 
(Peprotech). Cells at this stage were expanded for 7-10 days prior to gentle dissociation into 
small clumps with Accutase, and subsequently plated on laminin/poly-L-ornithine-coated 
plate in N3 medium supplemented with human 10 ng/ml brain-derived neurotrophic factor 
(BDNF) (Peprotech, INC, Cat. no. 450-02) and 10 ng/ml human GDNF (Peprotech, INC, 
Cat. no. 450-10) to support neuronal growth. Half of the spent medium was replaced with 
new medium daily for 2 weeks. For the neuronal maturation step, cells were gently 
dissociated with Accutase and plated at 1×104 cells on a glass 22mm coverslip coated with 
laminin/poly-L-ornithine  in a 6-well plate (see section 2.2.7) in 3N medium supplemented 
with 10 ng/ml BDNF and 10 ng/ml GDNF. From the first day of plating, cells were fed 
every 3 days by replacing half of the spent medium with new medium.  
2.2.8 Preparation of laminin/poly-L-ornithine-coated glass coverslips  
Glass coverslips (22 mm, VWR international, Cat no. 631-0158) were cleaned by soaking in 
70% nitric acid for 30 minutes and washed several times with water (Sigma, Cat no. 
W1503). Then, coverslips were sterilised by autoclaving before placing in each well of 6-
well culture plates. Coverslip were coated with 15 μg/ml poly-L-ornithine (Sigma, Cat. no. 
P4957) at room temperature overnight. After removal of poly-L-ornithine and washing with 
water for 3 times, the coverslips were air dried, and then subsequently coated with 10 μg/ml 
laminin (Sigma L2020-1MG) for 4 hours or overnight at 37°C. To prepare the plate for 
seeding of neural cells, laminin was aspirated and plating medium was added into the well. 




Immunostaining was performed on cells growing on a glass coverslips or in multi-well 
plates. Spent medium was removed gently and cells were immediately fixed with 4% PFA 
for 15 minutes. Then, cells were washed 3 times with PBS with 10-minutes incubation for 
each wash. Cells were permeabilized and blocked with 2% goat serum/0.1% Triton-X100 in 
PBS for 30 minutes prior to overnight incubation at 4°C with a primary antibody. Following 
primary antibody removal, cells were washed 3 times with PBS. Secondary antibody 
conjugated with a fluorescent dye was applied and incubated at room temperature for 1 hour 
in the dark. Following secondary antibody removal, cells were washed 3 times with PBS. 
Finally a coverslip was mounted on a clean glass slide using mounting medium (Vectashield, 
Cat. no. H-100). For long-term storage, nail polish was applied to seal the edge of coverslip 
with a glass slide. Stained cells were subjected to imaging immediately or stored at 4°C in 
dark conditions. The a-synuclein antibody used was developed against amino acids 15-123 
of rat a-synuclein, raised in mouse, and had been successfully tested in humans (BD 
Transduction laboratories, 1 in 500). 
2.2.10 Chromosome Counting 
After 45-48 hour of cell splitting, cell division was arrested with colchicine (Gibco, Cat 
no.15210-040). Cell were trypsinised and dissociated to single cells. Cells were then treated 
with a hypotonic solution, 0.075 M KCl, for 10-15 minutes at room temperature. After KCl 
removal, cells were fixed with a mixture of methanol and acetic acid in 3:1 ratio, and 
subsequently washed twice. Cell pellets were re-suspended in fixative and dropped on glass 
slide. Cells were allowed to air dry, and then stained in Giemsa dye. Finally, cells were 
mounted on glass slides with xylene and examined for chromosome number under a 
microscope with 100X objective. G-banding was kindly analysed by the transgenic service 
of SCRM (The University of Edinburgh, UK). 
2.2.11 MTS assay for measuring proliferation rate of hES cells 
Cell proliferation was measured in 96-well plates using CellTiter 96® AQueous One Solution 
Reagent (Promega, Cat. no. G3582). hES cells were dissociated into single cells with 
Accutase, and then plated on Matrigel-coated 96-well plates in mTeSR1 at a density of 
5×104 cells/well. To investigate cell proliferation over 8 days, a total number of 8 plates of a 
set of hESC lines were prepared, of which each plate contained triplicates of each cell line to 
be analysed. At the day of assay, 20 µl of the MTS reagent was added into each well, which 
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contained 100 µl spent medium. Cells were incubated at 37C in the incubator for 1 hour. 
The soluble formazan product was determined by measuring absorbance at 490 nm using a 
96-well plate reader (FLUOstar OPTIMA). The data was subtracted from background using 
a reading from control wells, which are wells without cells and contain 100 µl mTeSR1 and 
20 µl MTS. The assay was performed daily for 8 days. 
2.2.12 Western blotting 
Following removal of spent medium, cells were washed once with KnockOut™ DMEM/F-
12 (Gibco, Cat. no. 12660-012). Cells were then lysed at 4°C with occasional agitation for 
30 minutes with lysis buffer (120 mM Tris, pH 6.8, 4% SDS, 20% glycerol and 100 mM 
DTT) supplemented with protease inhibitor cocktail (Roche, Cat No. 04693159001). Cell 
lysate was transferred into an Eppendorf tube and sonicated until homogenous. Each lysate 
was incubated at 100°C for 5 minutes, and then placed on ice. Protein concentration was 
measured using the Bradford reagent (Sigma, Cat. no. B6916).  Protein samples were 
adjusted to equal concentration and subjected to SDS-PAGE immediately or stored at -80°C 
until use.  
Protein samples were diluted in 4X LDS sample buffer (Life Technologies, Cat. no. 
NP0007) supplemented with β-mercaptoethanol. Samples were boiled at 100°C for 5 min. 
Along with Seeblue® Plus2 pre-stained protein marker (Invitrogen, Cat. No. LC5925), 
protein samples were loaded onto NuPAGE® 4-12% Bis-Tris gel (Life Technologies, Cat. 
no. NP0322BOX). Electrophoresis was performed in NuPAGE® MES SDS running buffer 
gel (Life Technologies, Cat. no. NP0002) at 180 V for 1 hour. Then, protein was transferred 
onto Hybond ECL membrane (Amersham, Cat no. RPN203D), and blocked with 3% 
skimmed milk in 0.01% Tween 20, with agitation for 1 hour. After a brief rinse with 
washing buffer, membrane was incubated with a primary antibody against αSyn (BD 
Transduction, Cat. no. 610787) or β-actin (Sigma, Cat. no. A1978), which was diluted in 
blocking buffer. The membrane was washed three times prior to incubating with anti-mouse 
IgG HRP-conjugated secondary antibody (Promega, Cat No. W402B) for 1 h at room 
temperature. Following three washes, detection was performed using SuperSignal® West 
Femto Kit (Thermo Scientific, Cat no. 34094) and a film processor (Konica medical Film 
processor, SRX-101A).  
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2.2.13 ROS assay 
Production of cytosolic ROS was determined by live-imaging with dihydroethidium (dHEt) 
(Sigma, Cat. no. D7008). This is a blue fluorescent dye, which becomes oxidised by 
superoxide in cytosol and then binds DNA to produce red fluorescence. Measuring the rate 
of increase of nuclear red fluorescence gives a direct measure of dHEt oxidisation, which is 
indicative of ROS production within cells. The assay was performed on neurons growing on 
a 22-cm glass cover slip coated with laminin/poly-L-ornithine (see section 2.2.7). To load 
cells with dHEt, a cover slip was securely assembled within a chamber (ref). Cells were 
washed gently once with HBSS (Gibco, Cat. no. 14025), and then dHEt (5 μM) was applied 
into the chamber. Cells were imaged immediately to avoid intracellular accumulation of 
oxidized products. Imaging was performed with 10 second intervals using a fluorescent 
inverted microscope integrated with CCD camera (Hamamatsu, Orca ER).  Excitation light 
was generated from a Xenon arc lamp with beams passing through filters centred at 380 nm 
and 530 nm, and emitted fluorescence light was reflected through a 488 nm and 605 nm 
longpass filters. Obtained data were collected and analysed using software from Andor 
(Belfast, UK), by which ratio of emitted fluorescence, red:blue, was determined. 
In the experiments where more mature neurons were assayed, a fluorescent inverted 
microscope (Ziess) integrated with CCD camera (AxioCam MRM) and Axio Observer 
software with the same settings applied. Acquired data was analysed using ImageJ. In case 
that data filtering was applied, data was sorted based on average emitted blue fluorescence 
(designated as initial blue) of the first 3 frames of imaging. Data were classified into two 
groups; one with initial blue less than 30 and the other with initial blue equal to or more than 
30. 
2.2.14 RT-qPCR for total αSyn 
Total RNA was reverse transcribed in a final volume of 50 μl using Superscript III 
(Invitrogen, Cat. no. 18080-093). Firstly, 35.5 μl of a mixture containing 0.5 -1.5 μg of total 
RNA, 2 μl of 200 ng/μl of random primer and 2.5 μl of 10 mM dNTPs was heated to 65°C 
for 5 minutes, and then incubated on ice for 5 minutes. Next, the mixture was added to 14.5 
μl of reverse transcription mix containing 10 μl of 5x first strand buffer, 2.5 μl of 0.1 M 
DTT, 1 μl of RNase inhibitor and 1 μl of Superscript III Reverse Transcriptase. Reverse 
transcription was performed using a PCR machine (MJ Research, PTC-200 Peltier Thermal 
Cycler) with parameters as follows; 25°C for 5 minutes, 50°C for 60 minutes, and 70°C for 
15 minutes.  cDNA samples were used immediately or stored at 4°C. 
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A 10-μl qPCR reaction was set up with the Universal Probe Library (UPL) system (Roche), 
1 pmol/μl of each primer and cDNA. PCR was performed using a LightCycler 480 (Roche) 
with PCR parameters as follows: (95°C for 5 min), [(95°C for 10 sec) + (61°C for 10 sec)] 
for 45 cycles. Data was analysed by comparing C(T) to standard curves generated by qPCR 
of serial diluted cDNAs or plasmid DNA. The quantitation was performed using the 
comparative C(T) method (Schmittgen and Livak, 2008) and normalised to 18S rRNA as 
internal control. 
2.2.15 FACS Analysis  
Prior to cell detaching, hES cells were treated with 10 µM ROCK inhibitor for 1 hour. Cells 
were dissociated with Accutase (Gibco, Cat. no. A11105-01) and washed in FACS Buffer. 
To obtain single cell suspension, cells were filtered through cell strainers. FACS analysis 
was performed using a FACSCalibur flow cytometer (Becton Dickinson) with an acquisition 
rate of 1,000-3,000 events per second for a total of 10,000 events per sample.  Cells were 
excited with 488-nm laser, and green fluorescence was detected using 490 LP and 510/20 
filters. Data were further analysed and presented using FlowJo software (Tree Star, 
Ashland). All samples were performed in duplicate.   
Analysis of mES cells was similar to that of hES cells except that mES cells were detached 
and dissociated using trypsin/EDTA without prior treatment with ROCK inhibitor.  
2.2.16 Cell death assay 
This experiment was performed on differentiated neurons cultures on 22-mm glass 
coverslips (see section 2.2.7). To perform the assay, a coverslip was securely assembled with 
a metallic chamber, and cells were washed once with HBSS (Gibco, Cat. no. 14025). Cells 
were incubated 5 µM Hoechst 33342 (Sigma Cat. no. B2261) and 5 µM propidium idodide 
(PI) (Sigma, Cat. no. P-4170) in HBSS for 15 minutes in dark conditions. Images were 
captured using a Ziess fluorescent microscope with a 20x objective. Two excitation/emission 
filter sets; 380/535 nm for Hoechst and 555/645 nm for PI, were applied to acquire images. 
Four to five microscopic images covering 500-1000 nuclei were applied in data analysis 
using Velocity software. Cell nuclei that are double stained for both Hoechst and PI were 





2.2.17 Statistics  
The number of technical and biological repeats for each experiment is stated in each figure 
legend. Bar charts are shown with the mean and standard deviation. Statistical tests between 




Chapter 3  
Establishment of transgenic SNCA hESC lines 
 
3.1 Plasmids for transgenesis  
3.1.1 Plasmid design 
My aim in designing the αSyn over-expression construct was to obtain a high level of αSyn 
production in neurons without compromising the viability of the hES cells or any of the 
progenitors produced during neuronal differentiation. Two major factors I have considered 
are promoter strength and its activity in hES cells and differentiated neurons. Regarding 
these criterion, the constitutive CAG promoter has been chosen. This promoter, first 
developed in 1991, has been optimised to efficiently drive ubiquitous and high expression of 
a transgene in the majority of cell types (Niwa et al., 1991). Furthermore, it also has been 
applied in mES cells, in which its activity still maintains when the cells are differentiated 
(Alexopoulou et al., 2008; Chambers et al., 2003; Hadjantonakis et al., 1998).  
In order to rapidly identify hESC clones with differing levels of expression and to monitor 
transgene silencing a Venus reporter protein was linked to αSyn expression with an internal 
ribosome entry sequence (IRES). 
I have constructed two plasmids for the purpose of making transgenic hESC lines. The 
pCAG-SNCA-IRES-Venus (pCAG-SIV) plasmid is designed to express human wild-type 
αSyn and a fluorescent reporter protein, Venus. The control plasmid, pCAG-IRES-Venus 
(pCAG-IV), has an identical structure without the SNCA coding sequence (Figure 3.1).  
The pCAG-SIV construct contains the αSyn -encoding gene, SNCA, driven constitutively by 
the CAG promoter. Downstream of SNCA is an IRES linking the Venus-encoding gene, so 
that αSyn expression could be monitored in living cells by observing Venus fluorescence. 
The plasmid also has a puromycin-resistant gene, puromycin N-acetyl transferase, driven by 





Figure 3.1 Schemes of pCAG-SNCA-IRES-Venus and pCAG-IRES-Venus vectors. 
A) pCAG-SNCA-IRES-Venus. The plasmid contains 2 major elements: an αSyn (SNCA) 
and Venus expression cassette, and a drug-selectable cassette. The first element has a 
constitutive promoter pCAG to drive the expression of SNCA and Venus, by which the 
expression of SNCA was expected to be traced. The puromycin-resistant gene (Puror) serves 
as a selectable maker under the murine phosphoglycerate kinase (mPGK) promoter. 
B) pCAG-IRES-Venus. This control plasmid contains the same elements as pCAG-SNCA-
IRES-Venus with the exception of the SNCA coding sequence.  
mPGK pAPuro r SNCA IRES Venus pACAG
A




The control plasmid, pCAG-IV, contains the same elements as pCAG-SIV except that it 
does not contain SNCA.  
3.1.2 Plasmid construction 
Both expression plasmids were successfully constructed using the approaches shown in 
Figure 3.2 and Figure 3.3. DNA digests during plasmid engineering are shown in Figure 3.4. 
The final plasmids were analysed by restriction digestion (Figure 3.4F and 3.4G) and 
verified to be free of mutations by DNA sequencing (data not shown).   
Restriction digestion analysis shows that 4 out of 5 clones (no. 1, no. 2, no. 3, and no. 4) of 
pCAG-SIV have expected sizes of the inserts (Figure 3.4F). These clones were subjected to 
DNA sequence analysis, and only clone no. 1 and clone no. 3 had the correct orientation of 
the IRES-Venus element. As there were no mutations within the IRES-Venus region and 
SNCA gene in both clones, either of them could be applied for transgenesis. In this work, I 
have used clone no. 1. 
The control plasmid, pCAG-IV, was constructed by replacing the SNCA gene in pCAG-
SNCA with a PCR-amplified IRES-Venus product. Plasmid DNA of 5 bacterial 
transformants were enzymatically analysed for the IRES-Venus insert. Only clone no. 1 and 
clone no.2 had an insert with a size corresponding to IRES-Venus fragment (Figure 3.4G), 
thus they were further analysed by DNA sequencing. Since mutations in Venus were 
detected in clone no. 2 (positions 535-538), but not in clone no. 1, the latter was applied for 
transgenesis. 
3.2 Establishment of αSyn-overexpressing hESC lines 
3.2.1 Determination of optimal puromycin concentration for selection of 
hESC clones  
I have investigated the efficiency of puromycin in killing wild type Shef4 hES cells by 
treating them with various concentrations of the drug ranging from 0.125 µg/ ml to 2 µg/ ml. 
The cells were challenged with media containing puromycin for 12 days, and they were 
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Figure 3.2 Scheme of plasmid construction of the αSyn expression vector, pCAG-
SNCA-IRES-Venus. Step 1, the SNCA fragment was derived from pcDNA3.1-SNCA by 
PCR with a pair of primers containing additional enzymatic restriction sites; XhoI site for the 
forward primer (XSNCA-F) and NotI site for the reverse primer (NSNCA-R). Step 2, the 
PCR product was digested, purified, and then ligated in to between XhoI and NotI restriction 
sites of the pCAG-stuffer plasmid, yielding the plasmid pCAG-SNCA. Step 3, the IRES-
Venus element with NotI sites at both ends was derived from the FCT-IVpBS plasmid by 
PCR with the primers NVEN-F and NVEN-R. The PCR product was then cloned into the 
intermediate vector, pCR®-Blunt II-TOPO®. Step 4, the IRES-Venus fragment was digested 
from the intermediate vector, and then ligated into of the pCAG-SNCA at the NotI site, 
downstream of the SNCA element. This process resulted in a final plasmid construct, pCAG-
SNCA-IRES-Venus. The final plasmid was analysed for the correct orientation by enzymatic 




Figure 3.3 Scheme of plasmid construction of the Venus expression vector, pCAG-
IRES-Venus.  The SNCA fragment of pCAG-SNCA, which is an intermediate plasmid 
during construction of pCAG-SNCA-IRES-Venus, was replaced with the IRES-Venus 
fragment at the XhoI and NotI sites. The replacing element is derived from FCT-IVpB via 
PCR with indicated primers to create compatible restriction sites at both ends. The resulting 
plasmid has been analysed by enzymatic digestion and DNA sequencing. 
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Figure 3.4 Representative DNA gels of PCR products and digests.  
A) PCR product of SNCA and host plasmid (step 1  step 2, Figure 3.2). The SNCA 
fragment, amplified from pcDNA3.1-SNCA vector (lane 1), and pCAG-stuffer (lane 2) have 
been digested with NotI and XhoI. The bands of SNCA and pCAG backbone were excised, 
purified, and then ligated to make pCAG-SNCA. M: 1 Kb plus DNA ladder. 
B) Digestion analysis of pCAG-SNCA shows expected size of an insert corresponding to 
SNCA fragment. Plasmid DNA of two bacterial transformants was digested with NotI and 
XhoI. The result shows an insert with size corresponding to SNCA fragment. DNA 
sequencing of the insert confirmed correct sequences of SNCA (data not shown). M: 1 Kb 
plus DNA ladder, U: undigested, C: cut/digested. 
C) PCR product of IRES-Venus amplified from FCT IVpBS (step 3, Figure 3.2, and 
step 1, Figure 3.3).  
1: To construct pCAG-SNCA-IRES-Venus, the fragment was amplified with a primer pair 
that contains NotI sites at each end, NVEN-F and NVEN-R. 
2: To construct pCAG-IRES-Venus, the fragment was amplified by PCR with a forward 
primer with a XhoI site (XVEN-F) and reverse primer with a NotI site (NVEN-R). M: 1 Kb 
plus DNA ladder. 
D) Restriction analysis of Topo-IRES-Venus (step 3, Figure 3.2). Digestion with NotI 
shows that bacterial transformants clone no. 1 and clone no. 2 harbour an insert with a size 
corresponding to IRES-Venus. Clone no. 3 appeared to lack an insert. M: 1 Kb plus DNA 
ladder, U: undigested, C: cut/digested.  
E) Fragments of pCAG-SNCA and of IRES-Venus for making pCAG-SNCA-IRES-
Venus (step 4, Figure 3.2). pCAG-SNCA and Topo-IRES-Venus have been digested 
with NotI. The bands of linearized pCAG-SNCA and IRES-Venus were purified, and then 
ligated before transforming into E. coli DH5α. M: 1 Kb plus DNA ladder, 1: pCAG-SNCA, 
2 and 3: Topo-IRES-Venus clone no. 1 and clone no. 2. 
F) Restriction analysis of pCAG-SNCA-IRES-Venus shows expected size of inserts 
(step 5, Figure 3.2).   The IRES-Venus fragment from Topo-IRES-Venus clone no.1 was 
inserted into the NotI site of pCAG-SNCA. Double digestion with XhoI and NotI shows an 
insert with expected size corresponding to IRES-Venus in all transformants. However, DNA 
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sequencing showed only two clones, clone no.1 and clone no.3, had the correct orientation. 
M: 1 Kb plus DNA ladder, U: undigested, C: cut/digested. 
G) Restriction analysis of pCAG-IRES-Venus shows an insert with a size 
corresponding to the fragment of IRES-Venus (step 3, Figure 3.3). Plasmid DNA of two 
bacterial clones was digested with XhoI and NotI. The results reveal an insert with expected 
size corresponding to IRES-Venus fragment in both clones. DNA sequencing revealed only 
clone no. 1 to be free of mutations.  M: 1 Kb plus DNA ladder, U: undigested, C: 
cut/digested. 




On day 1, the treatment resulted in dramatic cell death at all concentrations (Figure 3.5). The 
degree of killing efficiency correlated well with the concentrations as expected. At the 
lowest concentration of 0.125 µg/ ml, cells survived better than those treated with higher 
concentrations.  On day 2, complete cell death was observed at the concentration of 0.5 µg/ 
ml or higher whereas surviving cells still remained at lower concentrations.  On day 5, 
complete cell death was observed at the concentration of 0.25 µg/ ml. However, there was a 
group of cells surviving in the 0.125 µg/ ml condition. 
From day 6 to day 12, the group of cells observed on day 5 at 0.125 µg/ml continued to 
proliferate and formed an obvious colony as shown in Figure 3.5. However, their growth rate 
was retarded compared to the control.  
To summarise, puromycin at 0.25 µg/ml and higher concentrations were able to completely 
kill hES cells within the experimental period of time, whereas 0.125 µg/ml puromycin 
allowed a degree of colony formation. Generally, the lowest drug concentration that is able 
to completely kill non-transfected cells within 7 days is considered as an optimal 
concentration to apply in drug selection for generating stable cell lines. Based on this 
principle, puromycin at the concentration of 0.25 µg/ml is the optimal concentration. 
However, as drug resistance has been observed when the concentration was just slightly 
lower, it raised the concern of using this concentration for selection. Furthermore, during 
colony formation of hES cells, the accessibility of drug to cells may be reduced, which may 
increase cell survival. Regarding this concern, I decided to use 0.5 ug/ml puromycin, which 
is the second lowest concentration that efficiently killed cells in this experiment. Consistent 
with other work, this concentration also has been used in the HB9 hESC line (Moore et al., 
2010) 
3.2.2 Optimisation of Shef4 hES cells electroporation 
Electroporation using the Neon System (Invitrogen, Carlsbad, CA, USA) has been shown to 
efficiently deliver exogenous DNA into hES cells to generate stable transfectant lines 
(Moore et al., 2010). Like other electroporation technologies, it is based on using an 
electrical current to induce pore formation in the plasma membrane to allow biological 
molecules to enter cells. The major advantage of the Neon System is it used gold-plated 
electrodes in a narrow electroporation chamber. This dramatically reduces and the number of 
cells needed for electroportation. However, optimisation of electroporation conditions for 




Figure 3.5 Puromycin kill curve.  Wild-type Shef4 hES cells were treated with puromycin 
at different concentrations (0.125 – 2.0 μg/ml) for 12 days to find an optimal concentration 
for drug selection during the generation of stable transgenic hESC lines. 
  
Control                      
(µg/ ml)
0.125
0.25                     
0.5                      
1.0                        
2.0
Day 0 Day 1 Day 2 Day 12
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be the hard-to-transfect cells, in which low genomic integration frequency of introduced 
exogenous DNA have been reported. Therefore, to increase the chance of integration, 
efficient transfection is required. High cell viability and maximum transfection efficiency are 
the major aims of this optimisation. 
Since electroporation efficiency is mainly dependent on the combination of three parameters; 
the electric field, pulse width, and pulse number, I have varied these parameters in four 
different electroporation conditions (Table 3.1).  To investigate the transfection efficiency of 
each condition, Shef4 cells were electroporated with pCAG-GFP, kindly provided by 
Agnieszka Paca, a former PhD student in the Kunath lab.  At 40 hours post-electroporation, 
cells were examined for numbers of total surviving cells using Trypan blue. Cells were also 
analysed for GFP expression by fluorescent microscopy and flow cytometry.   
Total viable cell counts showed that electroporation reduces cell viability approximately 
40% to 70% when compared to the controls (Table 3.2). The viability of cells appeared 
inversely correlated with the intensity of GFP and percentage of fluorescent cells. By 
fluorescent microscopy, condition D gave the highest proportion of cells with intense GFP, 
but also resulted in the lowest cell survival rate (Table 3.2 and Figure 3.6). Condition F gave 
a higher cell survival rate; however, it produced the lowest proportion of fluorescent cells. 
Consistent with the microscopic observations, FACS analysis showed that condition D gave 
the highest percentage of GFP-expressing cells (57%), and importantly the highest 
proportion with intense fluorescence (18%) (Figure3.7). These results indicate that among 
the tested conditions, condition D provided the highest efficiency of delivering plasmid 
DNA into hES cells with acceptable cell viability. Thus I have applied this condition to 
transfect Shef4 hES cells with the pCAG-SIV and pCAG-IV plasmids. 
3.2.3 Electroporation of  Shef4 hES cells with pCAG-SIV or pCAG-IV  
The electroporation was performed using condition D optimised previously. Microscopic 
observation for the Venus fluorescent protein at 24 hours post- electroporation showed that 
cells electroporated with pCAG-SIV were negative for Venus fluorescence whereas those 
with pCAG-IV showed only rare fluorescent cells (Figure 3.8). However, the pCAG-GFP 
produced robust GFP fluorescence in transfected cells. According to this, the absence of 
Venus expression in Shef4 cells transfected with pCAG-SIV is unlikely to be due to the 




Figure 3.6 GFP fluorescence at 40 hours post-electroporation. To optimise the 
electroporation of plasmid DNA into Shef4 hES cells, cells were electroporated with pCAG-
GFP in different electroporation conditions (A to F, see Table 3.1). Condition C and 















Figure 3.7 FACS analysis of GFP-expressing Shef4 hES cells after electroporation of 
pCAG-GFP. Cells were analysed by FACS 40 hours after electroporation to determine 
DNA-delivery efficiency. Condition D gave the highest percentage of GFP-positive cells, 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































dition B (negative control)
Shef4 electroporated without pCAG-GFP
All conditions (merged)
Condition C Condition D
Condition E Condition F
 Control B 1.75 
 Condition C 53.5 
 Condition D 57.4 
 Condition E 48.4 




Figure 3.8 Shef4 cells 24 hours after electroporation with pCAG-SNCA-IRES-Venus or 
pCAG-IRES-Venus. GFP fluorescence in electroporated cells was investigated under by 
fluorescence microscopy. Cells electroporated with pCAG-SNCA-IRES-Venus exhibited no 
fluorescence. Rare cells electroporated with pCAG-IRES-Venus exhibited fluorescence (not 
shown). The cells delivered with pCAG-GFP showed robust GFP fluorescence.  
4X (phase)
Shef4 + pCAG-GFP
Shef4, electroporated without DNA
Shef4+pCAG-SNCA-IRES-Venus
Shef4+pCAG–IRES-Venus
10X (phase) 10X (fluorescent)
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Table 3.1 Optimisation of Shef4 hES cell electroporation conditions with pCAG-GFP. 
Code of  conditions DNA Voltage Pulse width (ms) Pulse 
A pCAG-GFP - - - 
B - 1400 20 1 
C pCAG-GFP 1400 20 1 
D pCAG-GFP 1200 20 2 
E pCAG-GFP 1050 30 2 
F pCAG-GFP 950 30 2 
 
Table 3.2 Cell viability and qualitative assessment of GFP fluorescence at 20 hours 
post-electroporation.   
Conditions Total viable cells Observation under a microscope 
A 1.48105 few green cells 
B 1.43105 no green cells 
C 8.4104 variable fluorescent intensity within green cells 
D 4.6104 high proportion of intense green cells 
E 7.2104 
number of green cells comparable to Condition D, but with 
weaker fluorescent signal 





I proceeded with puromycin selection, colony picking and expansion of these cells. In the 
meantime, I investigated Venus fluorescence under a fluorescent microscope regularly. In 
cells transfected with the plasmid control, pCAG-IV, Venus fluorescence was clearly seen in 
a majority of colonies (Table 3.3 and Figure 3.9A). However, there was no Venus signal in 
cells transfected with pCAG-SIV.  
As it is possible that Venus expression was lower than that the fluorescent microscope can 
detect, I decided to use a more sensitive technique to examine the expression. I performed 
indirect immunostaining for Venus using an antibody against GFP (kindly provided by 
Mattias Malaguti from Sally Lowell’s lab, MRC CRM) in conjunction with a fluorescent–
conjugated secondary antibody. The GFP antibody was able to recognise Venus, as shown in 
the Shef4-IV clone no. 6 (Figure 3.9B).  However, none of the clonal lines with pCAG-SIV 
were immuno-positive for this antibody (Figure 3.9B).  
Consistent results were obtained for the two different methods of detection, indicating that 
cells transfected with pCAG-SIV must have produced very low level of Venus protein or in 
worst case, did not produce Venus at all. Failure to express Venus is unlikely to be due of a 
lack of activity of the CAG promoter, as the same promoter was able to drive Venus 
expression in pCAG-IV. Possible causes of the failure in Venus expression in Shef-SIV 
clones are listed as follows. 
1. The IRES did not function or functions poorly in recruiting ribosomes for protein 
translation. 
2. The IRES-Venus fragment was mutated or removed from the plasmid backbone 
before or during integration into the host genome. 
3. The IRES function is normal, but there is selection for cells that produce very low 
Venus levels, which can occur when the transgenic protein is toxic to cells.  In this 
case, only cells that have a tolerable level of αSyn can survive. 
As different cell lines respond to toxic proteins differently, I have investigated how the 
transgene plasmids work in mES cells, which are easier to grow and expand more rapidly 






Figure 3.9 Venus expression in Shef4 hES cells transgenic for pCAG-SNCA-IRES-
Venus (SIV) or pCAG-IRES-Venus (IV). 
A) Venus expression in expanding clonal lines of transgenic Shef4. Representative 
images of Shef4-SIV and Shef4-IV clonal lines are shown. Venus has observed under a 
fluorescent microscope. Note that Shef4-IV clone no. 1 is positive for Venus, whereas two 
Shef4-SIV clones are negative. 
B) Anti-GFP immunostaining of Shef4 transgenic clones. Representative images of 
Shef4-SIV and Shef4-IV clonal lines immunostained for Venus and observed under a 
fluorescent microscope are shown. Shef4-IV clone no. 6 is positive for the anti-GFP 
antibody, whereas two Shef4-SIV clones are negative. Shef4-IV, Shef4 with stable 




Table 3.3 Number of Venus-ve and Venus+ve clonal lines for Shef4-SIV and Shef4-IV. 
Line Total clonal lines Venus+ve Venus-ve %Venus+ve 
Shef4-SIV 11 0 11 0 





3.2.4 Transfection of mES cells with pCAG-SIV  
The mES cell line, E14Tg2a, was transfected with pCAG-SIV using LipofectamineTM 2000 
(this experiment was performed by William Hamilton, a former PhD student in the Kunath 
lab).  At 16 hours post-transfection, cells were examined for Venus expression under a 
fluorescent microscope. Unlike Shef4 hES cells, a large percentage of transfected mES cells 
exhibited robust Venus fluorescence as shown in Figure 3.10A. The same result was also 
observed for mES cells transfected with pCAG-IV (data not shown). 
I further investigated Venus fluorescence in the transfected population using FACS. The 
analysis showed that pCAG-IV gave a higher percentage of fluorescent cells than pCAG-
SIV; 54% versus 31%, respectively (Figure 3.10B). Moreover, transfection with pCAG-IV 
produced a population with intense fluorescence, as indicated by a narrow sharp peak at the 
bottom right of the graph, which is absent in those transfected with pCAG-SIV (Figure 
3.10B).  
The transfected mES cells underwent puromycin selection and the total numbers of drug-
resistant colonies were counted for each construct. The pCAG-IV produced more colonies 
than pCAG-SIV; 488 versus 395, respectively (Table 3.4). Approximately 50% of the 
colonies with the pCAG-IV are fluorescent, whereas only 15% of the colonies with SNCA 
expressing plasmid are fluorescent (Table 3.4). A smaller number of Venus-positive colonies 
obtained from the pCAG-SIV construct are consistent with the FACS results (Figure 3.10B). 
Regarding the plasmid components, pCAG-IV and pCAG-SIV are very similar except that 
the latter plasmid has SNCA (Figure 3.1). It was interesting that without SNCA, cells 
appeared to survive better; mES cells transfected with pCAG-IV gave more puromycin-
resistant colonies compared to pCAG-SIV. However, this is considered under the 
assumption that these two plasmids have equivalent transfection efficiency. If this is indeed 
the case, the results might indicate that there is a selection mechanism against cells that have 
high levels of αSyn expression. High αSyn protein produced by the SNCA transgene might 
be toxic to cells, producing a smaller number of colonies and less colonies with Venus 
fluorescence (Table 3.4). 
This hypothesis fits well with the FACS observations where pCAG-IV produced higher 
percentage of Venus fluorescent cells, as well as generated a population with intense Venus 





Figure 3.10 The pCAG-SNCA-IRES-Venus and pCAG-IRES-Venus constructs are 
able to drive the Venus expression in mouse ES cells. A) Fluorescence microscopy of 
pCAG-SNCA-IRES-Venus in mouse ES cells. Mouse ES cells were transfected with pCAG-
SNCA-IRES-Venus, and observed under a fluorescent microscope at 16 hours post-
transfection. B) FACS analysis for Venus in mES cells with either pCAG-SNCA-IRES-
Venus or pCAG-IRES-Venus. Cells were analysed by FACS for Venus expression 16 hours 
after transfection. Both plasmids produced detectable fluorescent protein in mES cells. Note 
that the pCAG-IRES-Venus plasmid gave a higher percentage of Venus-positive cells, 
including an extremely fluorescent population (at ~104 FL1) that was absent in cells 
transfected with the αSyn-expressing plasmid.  






Table 3.4 Number of Venus fluorescent colonies following transfection of mES cells 
with pCAG-SNCA-IRES-Venus (pCAG-SIV) and the control plasmid (pCAG-IV). 
 pCAG-IV pCAG-SIV 
Total drug-resistant colonies 488  395 





is a bicistronic expression vector, from which a single mRNA produces both αSyn and 
Venus. If selection against high αSyn expression had occurred, there would be a 
corresponding decrease in Venus expression.  
However, low Venus expression from pCAG-SIV could also occur without any underlying 
selection mechanisms. The second gene downstream of an IRES in a bicistronic vector has 
been known to produce less protein compared to the coding sequence located immediately 
downstream of the promoter (Kim et al., 2004). Based on this, higher Venus expression from 
pCAG-IV could be because it does not have an upstream coding sequence as does pCAG-
SIV. 
3.2.5  Transfection of Shef4 hES cells using Lipofectamine® LTX 
Transfection of pCAG-SIV and pCAG-IV constructs with Lipofectamine® LTX into mES 
cells gave many robust puromycin-resistant colonies (>300). However, electroporation of the 
same constructs in Shef4 hES cells gave less than 20 puromycin-resistant colonies. The 
difference in colony number could be from the nature of cells and/or DNA delivery 
approaches. To increase the number of Shef4 transgenic lines and potentially identify a 
pCAG-SIV clone that expresses Venus, I applied a similar transfection approach to Shef4 
hES cells.  
Shef4 hES cells were transfected with pCAG-SIV and pCAG-IV using Lipofectamine® 
LTX. At early as 16 hours post-transfection, both plasmids gave rise to a few Venus 
fluorescent cells within transfected colonies whereas many fluorescent cells were observed 
in cells transfected with pCAG-GFP (Figure 3.11). The few Venus fluorescent cells observed 
from transfection with pCAG-IV or pCAG-SIV disappeared when cells underwent 
puromycin selection and clonal expansion. FACS analysis for Venus expression confirmed 
the absence of fluorescent cells in these transgenic Shef4 cell lines (performed by Masumi 
Nagano, a visiting Postdoctoral researcher in the Kunath group) (Figure 3.12). 
It is worth noting that using different DNA delivery approaches with the pCAG-SIV 
constructs never produced stable Venus fluorescent cells in Shef4 hES cells, which is 
strikingly different from that in mES cells. Whether mES cells are more capable to tolerate 
an increased αSyn load than hES cells, or the IRES element is preferentially active in mES 





Figure 3.11 Using Lipofectamine® LTX to make additional Shef4 clonal lines. With a 
similar DNA delivery method to that of mES cells, Venus is not observed in very few Shef4 
hES cells. Note that pCAG-GFP serves as a positive control for the transfection and images 












Figure 3.12 FACS analysis for Venus expression in clonal transgenic Shef4 lines. To 
further investigate the presence of Venus in clonal lines, cells at later passage are subjected 
to FACS analysis. A) and B) are representative FACS results obtained from two independent 
experiments. The transgenic lines are negative for Venus as shown by the comparable 
distribution of cell populations to that of wild-type Shef4, the negative control for Venus. 
Passage numbers of each clonal line are as follows; Shef4 p62 in A) and p56 in B), S22 
p69+18, S36 p69+17, S8 p62+25, S13 p69+14. Note that the former numbers indicate the 
passage number of the parental line Shef4 when first used to generate the transgenic lines, 
and the latter numbers are the number of passages after the clones have been established. 

















I have derived more puromycin-resistant hESC colonies using the LipofectamineTM method 
compared to that with electroporation using the Neon System (data not shown). This might 
be due to reduced toxicity of the LipofectamineTM transfection method. I have picked robust 
colonies with good hESC morphology to expand into clonal lines. Table 3.5 summaries the 
total number of clonal pCAG-IV and pCAG-SIV transgenic Shef4 lines derived using each 
of these two methods. 
3.2.6 RT-qPCR for total SNCA 
The absence of Venus expression in Shef4-SIV lines does not necessarily mean that SNCA is 
not expressed. Venus fluorescence in mES cells transfected with pCAG-SIV indicated that 
the mRNA of SNCA-IRES-Venus must have been successfully produced. Failure to detect 
Venus fluorescence in the Shef4-SIV might be a problem specific to the IRES in hES cells. 
Regardless of the reason, it was reasonable to investigate the level of SNCA expression in 
these cells.  
I investigated the level of total SNCA mRNA expression by reverse transcriptase-quantitative 
PCR (RT-qPCR). I extracted total RNA from expanding puromycin-resistant colonies of 
Shef4-IV and Shef4-SIV clonal hESC lines, and then performed RT-qPCR. As shown in 
Figure 3.13, most of the Shef4-SIV lines have an elevated level of SNCA; 17 out of 29 lines 
have more than 3-fold increased expression of SNCA to that of the wild-type Shef4 cells. The 
highest level of SNCA expression was observed in Shef4-SIV cell line no. 36 (S36, Figure 
3.13). The RT-qPCR results were also consistent with immunostaining for αSyn (Figure 
3.14). An increase in SNCA expression indicated that the SNCA transgene must have 
integrated in the genomic DNA of the Shef4-SIV cell lines. However, it is clear that Venus 
expression cannot be used to indicate SNCA transgene activity in these cell lines. Instead, the 
SNCA level must be examined by RT-qPCR and further confirmed by western blotting.  
It is worth noting that even with high levels of α-synucelin, the transgenic hES cells still 
remained undifferentiated and maintained typical hESC morphology (Figure 3.9), normal 
chromosome counts (data not shown), and expression of the pluripotency factor OCT4 
(Figure 3.14). However, there is still a concern that the increased level of SNCA will affect 





Figure 3.13 RT-qPCR for total SNCA in undifferentiated transgenic Shef4 hESC lines. 
The data has been normalized to 18S rRNA, and shown relative to the parental line, Shef4.  
V and S lines harbour pCAG-IV and pCAG-SIV, respectively. Each bar represents the mean 
and standard deviation of 3 technical replicates. These qPCRs were done at different time 
points and passage numbers, but a control sample was used each time and the data are 
































































































Figure 3.14 Immunostaining of undifferentiated ES cells and iPS cells for total α-Syn 
and Oct4. The immunostaining conditions were carefully controlled to ensure that all cells 
were treated the same throughout the staining process. For example, the same antibody batch 
and concentration, incubation time. To image αSyn, two fixed settings; short- and long 








DAPI                            Oct4                        α-Syn (low)                   α-Syn (high)
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Table 3.5 Number of total clonal lines established in this study. The lines have been 
generated using two different DNA delivery strategies; electroporation and transfection 
using Lipofectamine® LTX. 
Lines Electroporation Transfection Total clonal lines 
Shef4-SIV 9* 20 29 
Shef4-IV 11 9 20 
 





3.2.7 Transgene silencing during passages 
One of the common difficulties in generating stable transgene expressing hESC lines is the 
stability of the transgene expression. The stable transfection outcome varies between cell 
lines and the promoter of choice (Liew et al., 2007; Liu et al., 2009b). Many promoters 
showed robust transient expression but failed to retain the expression after drug selection and 
long-term culture. The pCAG promoter has been reported to drive stable transgene 
expression in undifferentiated mouse ES cells, and to maintain expression in all 
differentiated derivatives (Alexopoulou; Hadjantonakis et al., 1998). Similar to mES cells, 
stable transgenic hESC lines have been successfully generated using the CAG promoter 
(Liew et al., 2007; Seguin et al., 2008). Results from Draper and colleagues showed that 
although gene silencing was observed with the pCAG promoter, its incidence was less than 
observed for four other experimental promoters (Liew et al., 2007). 
I have investigated the stability of the SNCA transgene in undifferentiated transgenic Shef4 
hESC lines during continuous passaging by quantifying total SNCA mRNA levels in these 
cells at early and late passages. One out of 5 Shef4-SIV clonal lines had a dramatic reduction 
of total SNCA at later passages (Figure 3.15). Although the other four clonal lines still 
maintained high expression, their expression levels decreased slightly. These results indicate 
that some SNCA transgene silencing is occurring, but it is not widespread. Quantifying 
endogenous and exogenous SNCA expression separately should be able to more accurately 
monitor this. The potential for transgene silencing suggests that SNCA expression in the 
Shef4-SIV hESC lines should always be examined when conducting experiments with them.  
Chapter 4 will examine whether the transgene is silenced when the hES cells have undergone 
differentiation towards neurons.   
3.2.8 MTS assay for cell proliferation 
During clonal line expansion of transgenic Shef4 cells, I have noticed that some cell lines 
required cell passaging more often than others, raising the question whether αSyn can affect 
the proliferation rate of hES cells. Therefore, I investigated the correlation between cell 
proliferation rate and SNCA expression level in these cells. I divided the cell lines into two 
groups based on SNCA level assessed by RT-qPCR, namely low and high SNCA expression. 
I then employed a colorimetric assay, CellTiter96® AQueous One Solution Cell Proliferation 
Assay (MTS assay), to measure cell proliferation. The assay utilises a compound called MTS 




Figure 3.15 RT-qPCR for SNCA shows gene silencing in transgenic ES cells during 
passages. RT-qPCR has been carried out in early and late passages; passages 2 or 3 and 
passages 12 or 13 for early and late passages, respectively. Please note that S9 shows a 
reduction in SNCA expression in later passages. The data has been normalized to 18S rRNA, 
and shown in relative to the parental line, Shef4. Each bar represents the mean and standard 
deviation of 3 technical replicates. V: cell lines harbouring pCAG-IV, S: cell lines 
harbouring pCAG-SIV.   
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The process results in production of a soluble colour substance, known as formazan product, 
which specifically absorbs light at 490 nm. As the production of the formazan product is 
dependent on NADH or NADPH, which is produced by metabolic active cells, the amount of 
absorbance is proportional to the number of living cells in culture.  
I initially validated the assay by investigating whether the absorbance and cell numbers are 
correlated. The analysis showed that there is a strong positive correlation between these two 
factors (R2=0.98, P<0.05) when the cells are plated at a range between 3.8×104 cells/well to 
20×104 cells/well (Figure 3.16). The results were obtained from two independent cell lines 
and performed in triplicate. I have chosen a cell density of 5×104 cells/well, the second 
lowest density that showed strong correlation with cell survival, for later experiments. This 
will prevent over-crowding of cells near the end of the experiment. 
I assessed cell proliferation of the transgenic hESC lines using the conditions optimised 
above. The analysis revealed no statistically significant difference in the proliferation rates 
between two groups of cells as shown in Figure 3.17 and Figure 3.18A (Student’s-t test, P > 
0.05). Linear regression also indicated no significant correlation between SNCA expression 
levels and the proliferation rates of the cell lines (R2 = 0.003, P = 0.884, Figure 3.18). It is 
also notable that there is no significant difference in cell survival between these groups of 
cells, as shown by the results of MTS assay at 24 hour post-plating (Figure 3.17). These 
results indicate that SNCA level does not affect hESC proliferation and survival of 
undifferentiated hES cells.  
Variation of properties among the transgenic Shef4 hESC clonal lines is not correlated with 
SNCA levels, but might have been caused by two major factors – clonal variation and 
random integration of the transgene plasmids in the host genome. It is well known that hES 
cells are comprised of heterogeneous cell populations, in which sub-populations differ in 
functional properties (Stewart et al., 2006). Variation in clonal lines of hESC lines has also 
been reported (Heins et al., 2006). It must be acknowledged that these functional differences 
might have complications in response to an elevation of α-sunuclein. Although less likely, 
the clonal variation might be caused by random integration of transgenes into critical areas 






Figure 3.16 Determining suitable seeding density for cell proliferation assay using the 
CellTiter96® AQueous One Solution reagent (MTS assay). Two transgenic Shef4 hESC 
lines (S8 and S37) were seeded as single cells at various densities in mTeRS1 medium in 96-
well plates coated with GFR-MatrigelTM. After 24 hours of incubation, the plates are 
collected for MTS assay, for which absorbance for each cell line was measured at 490 nm 
(A, C). Data at each cell density was obtained from triplicate samples.  A strong linear 
relationship between cell number and absorbance was observed when cells were plated 
within a range of 3.38 × 104 cells/well to 20 × 104 cells/well, as indicated by the correlation 






Figure 3.17 Cell proliferation of transgenic Shef4 hESC lines. The MTS assay was 
performed daily over a period of 10 days post seeding for six Low αSyn lines (A) and three 
High αSyn lines (B) seeded in three wells each. Proliferation curves have been constructed 
using the means of absorbance at 490 nm of triplicate samples (n=1). Note that the S8 data 






Figure 3.18 Effects of SNCA level on the proliferation rate of hESC lines. For each cell 
line, the proliferation is the slope of the linear trend line of the data obtained between Day 1 
to Day 6 based on results shown in Figure 3.17. The colours of the bars indicate groups of 
cells regarding their SNCA expression level; grey: a parental line, blue: low SNCA 
expression, red: high SNCA expression. Statistical analysis shows no significant difference 
of the proliferation rates between the low α-syn and high α-syn groups (Student’s-t test, P > 
0.05). Linear regression also indicates no significant correlation between SNCA expression 
levels and proliferation rates of the cell lines (R2 = 0.003, P = 0.884). A) and B) Rate of cell 
proliferation shown as of individual cell lines, and that shown as an average of each group, 
respectively. C) and D) SNCA expression level shown as of individual cell lines, and that 

































































































Characterisation of SNCA transgenic hESC lines 
Introduction 
In this chapter, I aimed to answer the following questions. 1) Is the level of SNCA transgene 
expression observed in hES cells maintained during differentiation into neural cells? 2) Does 
SNCA over-expression in undifferentiated hES cells affect their differentiation potential 
towards the neural lineage? 3) Does elevated αSyn increase reactive oxygen species (ROS) 
production and cell death in neurons? 
Firstly, I have shown that in many hESC clones, the SNCA transgene is stably expressed in 
differentiated neural cells. When transgenic Shef4 hES cells are differentiated down the 
neural lineage, the resulting cells exhibited an elevation of total SNCA expression when 
compared to the control lines. The results indicated that the pCAGS-SNCA transgene can 
successfully drive expression in neural cell types. 
Then, I investigated the correlation between SNCA expression in transgenic Shef4 hES cells 
and their neural differentiation potential, which was assessed by the expression of pan-neural 
genes, NCAM and MAPT. I have shown that there is no significant correlation between 
SNCA expression and the expression of either neuronal marker.  From these results, I 
concluded that SNCA over-expression in transgenic Shef4 hES cells is unlikely to affect their 
differentiation potential towards the neural lineage. 
4.1  
In the final part of this chapter, I differentiated transgenic Shef4 hESC lines into cortical 
neurons. I compared the rate of ROS production in neurons with high αSyn and control 
neurons with normal levels of αSyn expression. I found that young neurons with SNCA over-
expression exhibited a higher rate of ROS production when compared to the control neurons. 
However, when I investigated this effect in more mature neurons, the difference in ROS 
production was not observed. The issues related to these observations are discussed.SNCA 
transgene is stably expressed in neural cells differentiated from hES cells; however, 
transgene silencing occurred in some clonal lines. 
One of the major concerns with using transgenic hESC lines to investigate a specialised cell 
type is the stability of transgene expression during differentiation. As transgenes can be 
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silenced during any step of the differentiation, it is essential to check for maintenance of 
expression. 
To investigate whether SNCA transgene expression is maintained during neural induction 
and specification, I differentiated transgenic Shef4 hESC lines and parental Shef4 hES cells 
towards the neural lineage using a monolayer dual-Smad inhibition protocol (Chambers et 
al., 2009) (Figure 4.1A). The protocol combines inhibitors of BMP and Activin/Nodal 
signalling to induce neural differentiation of hES cells. The majority of neural cells produced 
by this protocol have forebrain identity and express the characteristic markers PAX6, OTX2 
and FOXG1 (Chambers et al., 2009). In this study, I used LDN-193189, a chemical BMP 
receptor antagonist, to replace Noggin as it exhibited higher efficacy to induce neural 
differentiation with lower cost.   
I first showed that neural induction using this protocol was efficient and robust. Transgenic 
S9 and parental Shef4 hES cells were differentiated towards the neural lineage as shown by 
expression of a neurectoderm cell fate determinant PAX6 and a neuronal marker TuJ1 after 
14 days of neural induction (Figure 4.1B). Consistent with the immunocytochemistry results, 
RT-qPCR revealed a significant increase in the expression of neuronal genes NCAM and 
MAPT (Figure 4.1C).  And as expected, SNCA expression also increased when hES cells 
were differentiated down the neural lineage for 11 days, compared to the undifferentiated 
state. Both the parental Shef4 hES cells and the transgenic S9 line exhibited a modest 
increase of SNCA expression between 2-4 fold (Figure 4.1C). Although S9 is a transgenic 
hESC line, it has a normal level of SNCA expression compared to undifferentiated parental 
Shef4 (Figure 3.13), and is therefore not considered an over-expression cell line.  One might 
be able to assume that the elevation of SNCA expression in S9 cells at day 11 is only driven 
by endogenous SNCA, not the SNCA transgene (Figure 4.1C).   
Then, I assessed total αSyn expression in 22 transgenic hESC lines by western blotting. By 
comparing the αSyn expression of the transgenic lines to that of the control lines, I identified 





Figure 4.1 Neural induction of transgenic Shef4 hESC lines. A) Schematic of dual-
SMAD inhibition protocol used to differentiate transgenic hESC lines towards 
neurectoderm. Human ES cells were fed daily with KSR medium supplemented with 
SB431542 and LDN-193189, inhibitors of TGF-β type I receptors and BMP receptors, 
respectively. From day 5 of differentiation, SB431542 was withdrawn and the KSR medium 
was gradually replaced by N2B27 medium. B) Immunocytochemistry for PAX6 and TuJ1 of 
neuralised transgenic Shef4 hESC line, S9. At day 14 of neural induction, the majority of 
cells expressed PAX6 and a number of TuJ1-positive neurons were also observed. C) RT-
qPCR for total SNCA, NCAM and MAPT at day 11 of neural induction. All three genes 
increased expression during neural induction and significant differences were not observed 




























































Figure 4.2 Quantification of αSyn protein levels in neural cells derived from transgenic 
Shef4 hESC lines. A) Western blot for total αSyn of neural cells (day 11). Transgenic Shef4 
hESC lines underwent neural induction for 11 days, when total cell lysates were harvested 
and processed. Neural induction was performed in 4 different batches and each western blot 
has samples labelled in different colours. Each batch had Shef4–IV cell lines (V lines) to 
serve as internal controls.  B) ImageJ quantification of αSyn western blots. αSyn is presented 
relative to internal control line (s) (V lines) in each batch of differentiation (n=1). The 
colours of the bars correspond to the western blots in A).  
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Although these measures do not discriminate between endogenous and transgenic αSyn, the 
normal level of expression in 6 control transgenic hESC lines (V2, V3, V7, V26, V27, and 
V28) suggests any observed over-expression is due to the SNCA transgene (Figure 4.2). 
One might argue that the αSyn over-expression in these transgenic lines could be due to 
better neural differentiation, since αSyn increases with neuronal maturity. To address this 
issue, I examined the expression of neuronal markers, NCAM and MAPT, and found that 
most lines differentiated to a similar extent (Figure 4.5). Thus SNCA over-expression in 
these cell lines is most likely to be contributed by the exogenous SNCA transgene rather than 
more neurons being generated. 
Gene silencing during neural differentiation seems to have occurred in some transgenic 
Shef4 hESC lines. Although regression analysis revealed a correlation between SNCA 
mRNA of undifferentiated hES cells (D0) and that of Day11-neural cells (R2=0.5987 P 
<0.0001, Figure 4.3). There are some transgenic Shef4 hESC lines, for example, S33, S35 
and S6, that exhibited high SNCA expression in the undifferentiated state, which then 
dropped to a near normal level at day 11 of differentiation; thus suggesting gene silencing 
during neural induction of these lines.  
In addition, I investigated the correlation between SNCA mRNA and αSyn protein at Day 11 
of neural differentiation. Surprisingly, I did not observe a significant correlation between 
mRNA and protein expression at this stage of neural differentiation (R2=0.1379 P=0.117, 
Figure 4.4). Considering that αSyn could be toxic to neural cells at this stage, those that have 
extremely high αSyn protein might die, while surviving cells may adopt mechanism to 
reduce protein levels without affecting SNCA mRNA expression. Therefore, to investigate 
SNCA expression in these transgenic hESC lines, it is essential to determine the protein level 
instead of solely relying on mRNA expression. 
4.2 Over-expression of αSyn in transgenic hESC lines does not perturb their 
ability to propagate and differentiate into neural lineages. 
A report by Schneider and colleagues (Schneider et al., 2007) showed that over-expression 
of αSyn in expanded populations of neural progenitors derived from human fetal cortex 
impaired gliogenesis of these cells. This raised a concern that constitutive over-expression of 




Figure 4.3 SNCA mRNA of undifferentiated transgenic hESC lines is positively 
correlated with SNCA expression in neural cells. A) Histogram shows RT-qPCR for 
SNCA expression in undifferentiated transgenic Shef4 cell lines (D0) and that of D11-neural 
differentiated cells.  Please note that the Day 0 and Day 11 RT-qPCR sets were performed 
independently; SNCA expression of D0 cells was relative to Shef4 hESC line whereas that of 
D11 cells was relative to transgenic V hESC lines. Each bar represents the mean and 
standard deviation of 3 technical replicates. B) Regression analysis of D0 and D11 SNCA 
expression revealed a significant positive correlation between SNCA mRNA of these two 
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Figure 4.4 SNCA mRNA levels are not always predictive of αSyn protein levels at day 
11 of neural differentiation. A) Histogram shows RT-qPCR for SNCA mRNA and αSyn 
protein, which is analysed by western blot, at day 11 of neural differentiation. B) Regression 
analysis of the αSyn expression revealed a lack of correlation between SNCA mRNA and 





Figure 4.5 SNCA expression level in undifferentiated transgenic hESC lines does not 
affect their neural differentiation potential. A) Histogram shows RT-qPCR for SNCA of 
undifferentiated transgenic Shef4 cell lines, and NCAM and MAPT at day 11 of neural 
differentiation. Each bar represents the mean and standard deviation of 3 technical replicates. 
B) Regression analysis of the expression levels of SNCA, NCAM and MAPT (shown in A) 
revealed no statistically significant correlation between SNCA and each of the neural markers 
at 95% confidence (P=0.761 and P=0.461 for NCAM and MAPT, respectively). 
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Thus I investigated the correlation between (i) SNCA expression in undifferentiated 
transgenic hESC lines and (ii) their differentiation potential towards the neural lineage. I 
found that there is a lack of correlation between the level of expression of SNCA and that of 
neuronal markers (R2 = 0.008, P = 0.761, for NCAM , and R2 = 0.019, P = 0.461for MAPT, 
Figure 4.5). These results suggested that these transgenic hESC lines retain their potential to 
differentiate towards the neural lineage despite the over-expression of αSyn and are suitable 
to generate neurons for further study.    
The result is also useful for selecting a pair of cell lines to do experiments.  When whole-cell 
lysate is used in western blotting to assess the total αSyn level of differentiated cells derived 
from each cell line, a comparable number of neurons generated by each individual is an 
essential factor to control. From the differentiation results (Figure 4.5), the transgenic hESC 
lines S12, S6, and S24 were excluded from further studies as their neural differentiation 
potential is significantly different from the others. 
4.3 Young neurons with αSyn over-expression exhibit increased ROS 
production while cell death is unchanged. 
Several studies have reported that aberrant αSyn elevates ROS production (Cremades et al., 
2012; Protter et al., 2012). To investigate whether this phenotype occurs in the current 
models, I have differentiated a pair of transgenic hESC clonal lines, S37 and S9, into cortical 
neurons and assessed ROS production. The S37 clone was chosen as it has high expression 
of αSyn in undifferentiated hES cells (Figure 4.2), and still maintained this high expression 
level when differentiated into neurons (Figure 4.6). The S9 clone was chosen as I had 
performed all of the previous experiments using this clone as the control. At 34 days of 
differentiation, the neurons were assessed for cytosolic ROS production using a 
dihydroethidium (dHEt) fluorescence-based real-time assay. This dye exhibits blue 
fluorescence in the cytosol, but upon oxidisation to ethidium it becomes localised to the 
nucleus and emits red fluorescence upon binding DNA. The increase in nuclear red 
fluorescence over time gives the rate of ROS production in cells. The αSyn over-expressing 
S37 neurons showed a higher rate of ROS production compared to the S9 control neurons at 
day 34 (Figure 4.7A). The same result was also observed at day 38 of differentiation (Figure 
4.7B). It is important to note that in both S9 and S37 neurons, ROS production increased 
with differentiation time (Figure 4.7C).   
The neurons at this stage were also assessed for percentage cell death using Hoechst 33342 




Figure 4.6 Neurons derived from transgenic hES cells over-expressing SNCA have 
elevated αSyn protein. A) Immunocytochemistry for αSyn in differentiated neuronal cells 
(day 34) showed higher immunofluorescence intensity in neurons derived from transgenic 
Shef4 clonal line no. 37 (S37), compared to those from the transgenic Shef4 clonal line no. 9 
(S9, control).  B) Western blot and ImageJ quantification of total αSyn in differentiated cells 
shown in A) revealed an elevation of αSyn in S37 neurons compared to the control neurons 
(S9) (n=1). An equal amount of total cell lysate was loaded for each sample and αSyn 
expression in S9 cells was set at 1 for quantification. This was not normalised to a house-
























Figure 4.7 Neurons over-expressing αSyn exhibited increased production of cytosolic 
ROS, but not increased cell death. A) – B) Graphs show cytosolic ROS production, as 
presented by HEt intensity, in neurons derived from a pair of transgenic Shef4 cell lines; S9 
(control) and S37 (SNCA-over-expressing) (n=1). Days of differentiation of neurons are 
indicated. Each point and error bars represent the mean and standard deviation of 20 
neuronal nuclei. C) Rate of ROS production calculated from the slopes of graphs shown in 
A) – B). Neurons with αSyn over-expression exhibited a higher rate of ROS production than 
the control neurons at all time-points. D) Histogram shows percentage of dead cells in each 
neuronal culture assayed using propidium iodide (PI) and Hoechst 33342. No significant 



























































































































mark dead cells, whereas a blue fluorescent dye, Hoechst 33342, which can enter both living 
and dead cells, thus marking the total cell population. The ratio of PI over Hoechst 33342 
gives the percentage of dead cells. The double-stained cells were imaged using a camera-
integrated microscope and analysed for percentage of cell death by counts of several fields (n 
≥ 100 nuclei). Surprisingly, despite the difference in rate of ROS production, there was no 
difference in percentage of dead cells between the S9 and S37 neurons using this assay 
(Figure 4.7D). 
4.4 No difference in ROS production in more mature neurons 
In previous experiments, the ROS production assay was performed in young neurons (day 
34-38), which are not an affected population in PD, a late-onset disease. Thus in this 
experiment, I investigated ROS production in more mature neurons with the hypothesis that 
an increase in ROS production might be more severe in those over-expressing αSyn. I 
compared neurons derived from S37, which consistently over-express αSyn, with those from 
the parental line Shef4.  
Along with these two cell lines, I also differentiated other cell lines including S22, S36 and a 
pair of iPS cell lines, AST18 and NAS2, to determine whether increased αSyn affected 
neural differentiation potential towards cortical neural lineage. S22 and S36 are transgenic 
Shef4 hESC lines; a control and a cell line over-expressing SNCA, respectively. AST18 and 
NAS2 are derived from a PD patient with SNCA triplication and a healthy first-degree 
relative, respectively. These two cell lines have been well characterised to ensure 
pluripotency and normal karyotype (Devine et al., 2011). The S9 clone was no longer used 
as was behaving differently due to it having a higher passage number. 
4.4.1 No significant difference in differentiation potential towards the cortical 
lineage in pluripotent cell lines expressing different level of αSyn 
At day 12 of cortical differentiation, cells were immunostained for PAX6, OTX1/2 and 
Vementin to determine the cortical identity (Figure 4.8). All cell lines were positive for these 
makers, which are proteins characteristic of cortical stem and progenitor cells (Shi et al., 
2012), indicating similar differentiation potential of these cell lines towards the cortical 
neural lineage (Figure 4.8). Moreover, the results suggested that over-expression of αSyn is 
unlikely to cause a major effect on neural induction towards the cortical lineage, further 





Figure 4.8 Neural progenitors derived from transgenic Shef4 cell lines and iPS cells 
express markers of cortical identity. Transgenic Shef4 hESC lines and iPS cells from a 
healthy control (NAS2) and SNCA triplication patient (AST18) were differentiated into 
neural progenitors using the dual-Smad inhibition method. At day 12 of differentiation, cells 
were fixed and immunostained for PAX6, Vimentin and OTX1/2, protein markers that 
represent cortical character (n=1). All cell lines were able to produce cortical progenitors as 
shown by robust immunostaining for these markers.  















4.4.2 Selective neuronal loss in neurons derived from transgenic hESC lines 
over-expressing αSyn, and survival of glia-like cells with high αSyn 
expression  
I then differentiated these neural cells to produce neurons. At day 72 of differentiation, 
neurons were investigated for αSyn expression (Figure 4.9A and Figure 4.9B). Western blot 
analysis of total αSyn protein revealed loss of αSyn over-expressing in the S36 cells, while 
other cell lines exhibited the expected results; AST18 neurons, which has SNCA triplication, 
had approximately twice αSyn level of that of the control iPS cell line, NAS2, and S37 
neurons had the highest αSyn level with approximately 3.5-4 fold of that of the controls 
including a parental line Shef4 and transgenic line S22. Unlike S37, S36 has a comparable 
αSyn level to that of the controls. 
The loss of αSyn over-expression during differentiation of S36 hES cells into neurons 
suggested the possibility of selective death of neurons with high αSyn expression. To 
investigate αSyn expression within S36 differentiated population, neurons were fluorescently 
immunostained for α- synuclein. Results revealed that S36 neurons have barely detectable 
αSyn (Figure 4.10). However, intense αSyn expression was seen in TuJ1-negative cells. 
These cells have large-flatten morphology similar to glia. 
When considered carefully, this phenomenon seems to have occurred in S37 cultures as well 
(Figure 4.10). Even though its differentiated population is enriched with cells that have 
intense αSyn expression, the majority of them are TuJ1-negative (Figure 4.10). It is most 
likely that the elevated αSyn level observed previously by western blotting is mainly 
contributed by these glia-like cells, not neurons. 
4.4.3 Heterogeneity in αSyn expression within neuronal population of control 
cell lines 
The fluorescent immunostaining for αSyn also revealed heterogeneous expression of αSyn  
within the neuronal population of control cell lines, which include a parental Shef4, 
transgenic S22 and a control iPS cell line, NAS2 (Figure 4.10). For each of these cell lines, 
αSyn expression varies dramatically within the neuronal population; some neurons had 
barely detected αSyn whist other showed intense expression (Figure 4.11). Unlike S36 and 





Figure 4.9 Loss of αSyn over-expression characteristic of day 72 cortical neurons 
derived from S36 transgenic Shef4 cell line. A) Western blotting for total αSyn in day 72 
culture lysates derived from transgenic hES cells and iPS cells. β-actin western blotting 
served as a loading control. B) ImageJ quantification of αSyn shown in A). α-Syn is shown 
relative to Shef4. Note that αSyn in S36 neurons reduced to normal levels whereas the 




























Figure 4.10 Immunocytochemistry for αSyn and TuJ1 in day 72 neurons. The 
expression of αSyn is heterogeneous between neurons derived from each cell line (n=1).  










Figure 4.11 Magnified images of Figures 4.10 shows reduced αSyn in a number of day 
72 neurons derived from S36 and S37 while the expression remain high in glia-like 
cells. Arrows and arrowheads indicate TuJ1-positive and TuJ1- negative cells, respectively. 












Figure 4.12 Immunocytochemistry shows a glia-neuron mixed population of day 72 
neuronal differentiated S36 and S37. Immunocytochemistry for TuJ1 and GFAP in 
differentiated cortical neuronal cells (day 72) revealed enrichment of GFAP-positive cells 





















4.4.4 Data analysis of ROS production rate 
I then investigated ROS production in day 72 differentiated population of S37 and Shef4. 
Analysis showed no significant difference in ROS production rate between these two cell 
lines (Figure 4.13). This result might be due to a drawback of the assay, which cannot 
distinguish cell types within the population; thus data from neurons and non-neuronal cells 
were pooled. In an attempt to distinguish sub-populations within each cell line, and then to 
compare the data from the  same sub-population of these two cell lines, I filtered the data 
based on the initial value of blue fluorescent intensity, which is the value detected at the 
beginning of the assay. Using this method, the data were separated into two sub-populations; 
one is that with the blue intensity lower than or equal to 30 and the other with a greater 
intensity. However, when the same sub-populations of each cell line were compared, the 





Figure 4.13 No significant difference in rate of ROS production in day 72 neurons. The 
assay for ROS production was performed in neurons derived from a pair of hESC lines; 
wild-type Shef4 (control) and transgenic Shef4 cell line over-expressing αSyn (S37). The 
data was processed in 2 different methods prior to analysis as usual. A) No data filtering, and 
B), data filtering based on the intensity of the blue fluorescent signal at the first experimental 
time point with an arbitrary cut-off value of 30 fluorescent units. Histograms show the ROS 
production rates for both unfiltered and filtered data. Note that there is no significant 
difference in ROS production rate in neurons derived from wild-type Shef4 and S37 hES 






























































































































































In this chapter I described a set of transgenic Shef4 hESC lines over-expressing SNCA. The 
cell lines were characterised for stable SNCA transgene expression, neural differentiation 
potential and cytosolic ROS production when differentiated into the neural lineage. 
4.5.1 Transgene silencing during neural differentiation 
I provided evidences supporting that most of the transgenic lines (Figure 4.2) stably 
expressed SNCA transgene during neural differentiation while gene silencing was observed 
in a few cell lines. The low frequency of developmental transgene silencing could 
considerably due to a promoter of choice, pCAGs, which has been reported for stably driving 
the expression of transgenes during differentiation of ES cells (Alexopoulou et al., 2008; 
Hadjantonakis et al., 1998). Theoretically, transgene silencing can occur through multiple 
mechanisms, including removing of the transgene, transcriptional silencing and enhanced 
mRNA degradation. However, the most common mechanism related to developmental gene 
silencing is transcriptional silencing, which involves changes of chromatin structure by DNA 
methylation and histone deacetylation to restrict access of transcription factors to the 
promoter (Cherry et al., 2000; Wang et al., 2007).  
4.5.2 Different differentiation potential among transgenic SNCA-Shef4 hESC 
lines 
I showed that a few transgenic cell lines exhibited considerably different differentiation 
potential from others. As this variation is not correlated with SNCA expression in the 
undifferentiated state, it is unlikely that it is a result of the differences in SNCA expression 
level. Rather, it is most likely to be caused by clonal variation of the hESC lines.  It is well 
documented that hESC populations are heterogenous, and they can have different 
transcriptional profiles, thus affecting their differentiation properties (Stewart et al., 2006). 
To avoid this effect, one should use the lines with similar neural differentiation potential for 
further phenotypic analysis. 
Over-expression of SNCA in human foetal cortical progenitor cells has been reported to 
impair gliogenesis without affecting cell death (Schneider et al., 2007). The direct effect of 
elevated SNCA on gliogenesis has not been investigated in this study. However, I observed 
considerable GFAP+ cells in the differentiated population from S37 and S36 lines (Figure 
4.12), which over-express SNCA.  As increased cell death due to elevated αSyn is suspected 
for these cell lines, enrichment of glia-like cells in this study could be the result of selective 
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neuronal cell death rather than cell fate change. The contradictory results between these two 
studies may be due to differences in transgene expression systems and experimental cell 
types. Work reported by Schneider and colleagues used viral infection at the stage of neural 
progenitors whereas present study employed constitutive expression in transgenic hESC 
lines. 
4.5.3 Increased ROS production rate may be increased in young neurons, 
but not in more mature neurons 
The contradictory results of the two ROS production analyses could be due to selective cell 
death of neurons that have very high αSyn expression as differentiation progresses. Although 
cell death has not been observed by the Hoechst 33342/PI assay in S37 neurons, the 
increased ROS production without change in cell death may imply the very early stages of 
phenotypic manifestation. The ROS production may get more severe over time, which could 
lead to cell death. Thus, by the time that second analysis took place in more mature neurons, 
there would be fewer neurons with high αSyn expression present. This is consistent with the 
finding that the differentiated population of S37 at day 34 exhibited robust and homogenous 
αSyn expression (Figure 4.6), whereas those at day 72 exhibited heterogeneous αSyn 
expression, and were composed mainly with glia-like cells and neurons with low level αSyn 
(Figure 4.10, Figure 4.11, and Figure 4.12).  
Further evidence supporting that selective cell death due to elevated SNCA exists for the S36 
line. This line exhibited very high αSyn expression in hES cells and at day 11 of 
differentiation (Figure 4.3), but by day 72 of differentiation the level of αSyn expression was 
undistinguishable from control lines (Figure 4.9). Similar to S37, the differentiated αSyn 
expressing S36 cells were mostly glial-like and very little neurons remained (Figure 4.10).  
In addition to cell death, phenotypic analysis at late differentiation is also complicated by the 
heterogeneity of cell types within the differentiated population. Obviously, this is not due to 
exogenous SNCA expression as it is also observed in the cell populations derived from the 
control hESC lines, such as, the parental Shef4 line. Rather, it is due the nature of the 
differentiation protocol used in this study that sequentially produces complex classes of 
cortical neurons as differentiation progresses (Shi et al., 2012) As a result, cells in later 
stages of differentiation may exhibit differences in maturity, neural subtype and importantly, 
SNCA expression.   
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Due to limitations discussed above, future phenotypic analysis should be performed in young 
neurons or possibly at time points before day 72 of differentiation, to capture the phenotypes, 
such as changes in ROS production and cell death. I would wish to replicate these 
experiments at least three times to ensure that the results are robust. I would also like to 
assess the amount of cell death using different assays, for example using TUNEL staining. 
The ROS production differences suggest that mitochondria may be involved, and so assays 
to determine whether these are dysfunctional would be very interesting. Finally, it would be 
interesting to examine the localisation of αSyn (especially the overexpressed a-synuclein) in 
cells by both confocal microscopy and immuno-electron microscopy using immuno-gold 
labelling. 
 
Furthermore, investigation of the effect of αSyn on glial cells would be very interesting to 
investigate further. Quantification of double staining of αSyn and glial fibrillary acidic 
protein (GFAP) would be very important to help the interpretation of these results. This 
would help address the problem which I have had with using mixed cell cultures, but 
actually also add to the data. After all, there are other neurodegenerative disease in which the 
major effect of the mutation is in the supporting cells (e.g. astrocytes) (e.g. vanishing white 




Discussion and conclusion 
 
Understanding the mechanisms underlying the disease process of synucleinopathies has been 
hampered by the lack of appropriate disease models. Most currently available models are 
devoid of either neuronal aspects or human genetic background, which may contribute to 
failures in manifesting disease phenotypes.  
The present research is aimed to establish a novel disease model that has neuronal aspects 
combined with a normal human genetic background. The hESC system was employed due to 
their genetic stability and ability to be genetically manipulated, thus giving an opportunity to 
model genetic forms of synucleinopathies. Additionally, their self-renewal and capacity to 
differentiate into neurons in vitro provides an unlimited access to human neurons. The focus 
is on increased expression of WT-SNCA, which represents one of the genetic forms of PD.  
5.1 Establishment of SNCA-transgenic Shef4 hESC lines and their 
characteristics. 
Employing random insertional transgenesis using a plasmid vector, a set of transgenic Shef4 
hESC lines constitutively expressing SNCA at different levels has been established. Instead 
of relying on the Venus reporter protein as expected, they required other approaches to 
detect the SNCA transgene expression, such as, RT-qPCR and western blotting, which were 
used successfully in this study. Failure in detecting Venus protein made it more complicated 
to identify hESC clones with differing levels of expression, not only during clonal selection 
but also in down-stream experiments. However, directly assessing SNCA expression became 
essential and highly recommended in this model system, in which the transgene could be 
silenced during hES cell propagation and neural differentiation.  
The transgenic SNCA hESC lines were able to propagate and self-renew as ES cells, and 
differentiate into neuronal cell types as well as control hESC lines. This shows that they are 
not significantly affected by SNCA expression level.  
However, some transgenic lines exhibited variable neural differentiation potential, which is 
likely to be due to hESC clonal variation as discussed in Chapter 4. Thus, it is recommended 
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that one should pair hESC lines with comparable efficiency of neural differentiation for 
further analysis. 
5.2 Phenotypic analyses revealed promising results indicating they are 
suitable to study early events of the disease process. 
The models were tested whether they were able to recapitulate disease phenotypes by mean 
of ROS production and cell death. Cortical neurons derived from a pair of transgenic hESC 
lines, one with high (S37) and the other with normal SNCA (S9, control) expression were 
subjected to analyses, which were performed in two time points, between day 34 to day 38 
and by day 72 of differentiation. The analyses revealed significantly increased ROS 
production in the S37 neurons compared to the control. This phenotype was observed only 
observed in young neurons, but absent in more mature neurons. The contradictory results are 
likely to be caused by selective cell death of neurons with high αSyn expression as 
differentiation progresses. The stress from elevated αSyn and heterogenous expression of the 
transgene in later differentiation might have a negative effect on neuronal survival, leading 
to selective cell death before the second analysis took place.  The unchanged cell death in 
young neurons could be due to insensitive assay used in this study. Employing more 
sensitive approach, such as using a longitudinal videomicroscopy to track neurons for 
extended periods of time (Bilican et al., 2012), would have assisted in detecting dynamic 
changes. 
Back to the research question of whether SNCA-transgenic hESC lines can be use as tools to 
model a genetic form of synucleinopathies, I would say that the models are not a panacea for 
all of the disease features. Due to cell death in prolong culture and the embryonic 
characteristics of the neurons produced from hES cells, the present model has limitations to 
recapitulate the late stage of the disease. Rather, increased ROS production in young neurons 
may represent an early event of the disease in human. If so, the model system should have an 
advantage to provide insights into early pathogenic changes in neurons, which are essential 
for developing effective approach to prevent the disease progression.  
In addition to recapitulating some major disease characteristics demonstrated in this study, 
there are promising reasons supporting that these transgenic SNCA-hESC lines have a 
potential to be extremely useful tools in studying synucleinophaties.  Firstly, the models 
system was capable to derive neurons with up to 10-fold difference in αSyn compared to the 
control. It is worth noting that current iPS cell lines with SNCA triplication produced neurons 
with only 2-fold increased αSyn (Devine et al., 2011). Secondly, this set of transgenic hESC 
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lines expresses different levels of SNCA, which should be beneficial to study allelic effect on 
disease phenotypes in vitro. The positive correlation between SNCA expression level and the 
severity of the disease was observed in human (Fuchs et al., 2007); however, this has not 
been demonstrated in vitro. Finally, the transgenic hESC lines have identical genetic 
background, which may help minimise the phenotypic interference contributed by genetic 
variation. 
For these reasons, even though the present cell lines are not perfect models of 
synucleinopathies, it is hoped that they will be used in concert with other models to 
accelerate the research in this field. 
5.3 Future research 
 Following are suggestions for future experiments to make more out of the model system and 
to over-come the limitations that exist in the current models.  
5.3.1 ROS assay and cell death in young neurons. 
Although the results provided in this study are statistically significant, the models have not 
been reassessed due to time limitation. To confirm the current results, it is recommended to 
repeat the experiments using the same transgenic Shef4 hESC lines with young neurons.  
5.3.2 Employing other protocols to generate a pure population of neurons.  
The current study employed a directed cortical differentiation to generate neurons to model 
the disease. This protocol produces complex classes of cortical neurons in a temporal manner 
as the differentiation progresses (Shi et al., 2012). The heterogeneity of the cell population 
caused difficulty when two cell lines are phenotypically compared. The example is ROS and 
cell death assays in this study, where cells have been analysed as a pooled population 
without separating neurons from glia.  As differential analysis is very difficult as 
demonstrated previously, producing a pure population of neuronal subtype, such as 
dopaminergic neurons, instead of a complex neuronal population should make phenotypic 





5.3.3 Mitochondrial assays in pure population of neurons when they are still 
young. 
This should be performed only after the experiments in this study (ROS and cell death assays 
in young cortical neurons) have been reassessed. The purpose is to further evaluate the 
models. As the phenotypes have been observed in young cortical neurons, the same results 
are expected in other neuronal subtypes that are affected in synucleinopathies. In addition, as 
mitochondria are closely associated with ROS production, it is interesting to investigate its 
function in the current models, which suffer from increase ROS. 
5.3.4 Establish a DOX-inducible system to permit SNCA induction at later 
times. 
Even though this study has provided initial results showing that over-expression of αSyn in 
transgenic hESC lines does not perturb their ability to propagate and differentiate into neural 
lineages, it is not ensure that the elevated protein does not have other impacts on cell 
biology. Changes of cell fate and differentiation due to over-expression of αSyn in neural 
progenitors have been reported (Schneider et al., 2007), however, this has not been observed 
in this study. With the DOX-inducible system, the SNCA expression would be controllable, 
allowing the expression to occur at a time point similar to natural developmental process. 
Thus there should not then be a problem with ES differentiation, but SNCA could be 
overexpressed in mature neurons, isolating this effect from an earlier developmental defect. 
5.3.5 Instead of pCAGS promoter, use a neuronal promoter, of knock-in a 
mutant SNCA gene into the human SNCA locus with CRISPR/Cas9 
technology. 
Instead of being controlled by a constitutive promoter, the SNCA expression can be 
controlled under the neuronal promoter, which allows the expression to occur in relation to 
neuronal development. The knock-in approach allows integration of the transgene in a 
precise location in the chromosome without disturbing other genomic area. This minimises 
the risk of phenotypes being due to random integrations. The level of gene expression can be 






5.3.6 How would I tackle the project if starting again 
Five years later, I would tackle this project in a different way as technologies have developed 
further. I would consider whether insertion of the genes would be better in a defined position 
– either using a locus such as the Rosa 26 or HPRT locus, or by positioning repeats into the 
endogenous SNCA locus, using Crispr-Cas9 technology. If I chose the Rosa26 or HPRT 
locus, then I would reconsider the promoter to be used, picking one with expression only 
after the NS cell stage, so that I could examine the effect on neuron development rather than 
NS cell development. I would very much like to over express αSyn  in dopaminergic neurons 
specifically, and there are now established protocols to efficiently grow dopaminergic 
neurons in culture – both in mouse and humans. It may well remain difficult to model a 
disease of ageing such as Parkinson’s disease in a dish where we keep cells alive for weeks 
to months rather than decades, and this is a possible limitation of this type of experiment, 
although I tried to overcome this by overexpressing the αSyn which leads to earlier disease 
in humans. Inducing stress in these cells may accelerate “ageing” in these cell cultures, 
bypassing the problem. An alternative is to take iPS cells from patients with genetic α-
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